var title_f18_37_19024="Folliculitis vulva";
var content_f18_37_19024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Folliculitis vulva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19024=[""].join("\n");
var outline_f18_37_19024=null;
var title_f18_37_19025="Peripheral ulcerative keratitis";
var content_f18_37_19025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Peripheral ulcerative keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral ulcerative keratitis (PUK) in a patient with&nbsp;rheumatoid arthritis who also has&nbsp;necrotizing scleritis posterior to the PUK.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of C Stephen Foster, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19025=[""].join("\n");
var outline_f18_37_19025=null;
var title_f18_37_19026="Algorithm for evaluation and management of possible ACS";
var content_f18_37_19026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation and management of patients suspected of having ACS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 685px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To facilitate interpretation of this algorithm and a more detailed discussion in the text, each box is assigned a letter code that reflects its level in the algorithm and a number that is allocated from left to right across the diagram on a given level.",
"    <div class=\"footnotes\">",
"     ACC/AHA: American College of Cardiology/American Heart Associations; ACS: acute coronary syndrome; ECG: electrocardiogram; LV: left ventricular.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19026=[""].join("\n");
var outline_f18_37_19026=null;
var title_f18_37_19027="Hyphal form of Sporothrix";
var content_f18_37_19027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sporothrix schenckii",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microscopic view of growth of S. schenckii at 25&deg;C. Thin septate hyphae with numerous attached conidia in bouquet-like arrangements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kauffman, C. Diagnosis and Treatment of Human Mycoses. Duane Hospenthal, ed. Humana Press. Copyright &copy; 2008 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19027=[""].join("\n");
var outline_f18_37_19027=null;
var title_f18_37_19028="Barium: Patient drug information";
var content_f18_37_19028=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Barium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     see \"Barium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Digibar&trade; 190;",
"     </li>",
"     <li>",
"      E-Z Cat&reg; Dry;",
"     </li>",
"     <li>",
"      E-Z-Cat&reg;;",
"     </li>",
"     <li>",
"      E-Z-Disk&trade;;",
"     </li>",
"     <li>",
"      E-Z-Dose&trade; with Liquid Polibar Plus&reg;;",
"     </li>",
"     <li>",
"      E-Z-HD&trade;;",
"     </li>",
"     <li>",
"      E-Z-Paque&reg;;",
"     </li>",
"     <li>",
"      E-Z-Paste&reg;;",
"     </li>",
"     <li>",
"      Entero Vu&trade;;",
"     </li>",
"     <li>",
"      Entero VU&trade; 24%;",
"     </li>",
"     <li>",
"      Entero-H&trade;;",
"     </li>",
"     <li>",
"      Esopho-Cat&reg;;",
"     </li>",
"     <li>",
"      Liquid Entero Vu&trade;;",
"     </li>",
"     <li>",
"      Liquid Polibar Plus&reg;;",
"     </li>",
"     <li>",
"      Liquid Polibar&reg;;",
"     </li>",
"     <li>",
"      Maxibar&trade;;",
"     </li>",
"     <li>",
"      Polibar&reg; ACB;",
"     </li>",
"     <li>",
"      Readi-Cat&reg;;",
"     </li>",
"     <li>",
"      Readi-Cat&reg; 2;",
"     </li>",
"     <li>",
"      Sensatrast&trade;;",
"     </li>",
"     <li>",
"      Tagitol&trade; V;",
"     </li>",
"     <li>",
"      Ultra-R&reg;;",
"     </li>",
"     <li>",
"      Varibar&reg; Honey;",
"     </li>",
"     <li>",
"      Varibar&reg; Nectar;",
"     </li>",
"     <li>",
"      Varibar&reg; Pudding;",
"     </li>",
"     <li>",
"      Varibar&reg; Thin Honey;",
"     </li>",
"     <li>",
"      Varibar&reg; Thin Liquid;",
"     </li>",
"     <li>",
"      VoLumen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray or an alike test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701588",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to barium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A swallowing tube (esophagus) and windpipe (trachea) that are not normal, hole in the GI (gastrointestinal) tract, bowel block, or thinning of the stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697951",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of stool to white.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695246",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given by mouth or rectally.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11976 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19028=[""].join("\n");
var outline_f18_37_19028=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139057\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015167\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015166\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015170\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015171\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015173\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015169\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015174\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015175\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=related_link\">",
"      Barium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_37_19029="Penicillin G benzathine: Pediatric drug information";
var content_f18_37_19029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Penicillin G benzathine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/50/12070?source=see_link\">",
"    see \"Penicillin G benzathine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44691?source=see_link\">",
"    see \"Penicillin G benzathine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7272304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bicillin&reg; L-A",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bicillin&reg; L-A",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Syphilis, congenital:",
"     </b>",
"     I.M.: 50,000 units/kg as a single dose (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/50/12070?source=see_link\">",
"      see \"Penicillin G benzathine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Group A streptococcal upper respiratory infection",
"     </b>",
"     (Gerber, 2009): I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rheumatic fever, primary prevention:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;27 kg: 600,000 units as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;27 kg: 1.2 million units as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rheumatic fever, secondary prevention:",
"     <b>",
"      Note:",
"     </b>",
"     Duration of secondary rheumatic fever prophylaxis varies: Rheumatic fever with carditis and residual heart disease: 10 years or until 40 years of age (whichever is longer), sometimes lifelong prophylaxis;         rheumatic fever with carditis but no residual heart disease: 10 years or until 21 years of age (whichever is longer); rheumatic fever without carditis: 5 years or until 21 years of age (whichever is longer)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;27 kg: 600,000 units every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;27 kg: 1.2 million units every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Syphilis:",
"     </b>",
"     (CDC, 2010;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012): I.M.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Primary, Secondary, or Early Latent (&lt;1 year duration): 50,000 units/kg once; maximum dose: 2.4 million units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Late Latent or Latent with unknown duration: 50,000 units/kg once weekly for 3 doses; maximum dose: 2.4 million units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Group A streptococcal upper respiratory infection:",
"     </b>",
"     I.M.: 1.2 million units as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Rheumatic fever, secondary prevention:",
"     </b>",
"     I.M.: 600,000 units twice monthly or 1.2 million units every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Syphilis:",
"     </b>",
"     (CDC, 2010): I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Primary, Secondary, or Early Latent (&lt;1 year duration): 2.4 million units as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Late Latent or Latent with unknown duration: 2.4 million units once weekly for 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neurosyphilis: Not indicated as single-drug therapy, but may be given once weekly for 3 weeks following I.V. treatment; refer to Penicillin G Parenteral/Aqueous monograph for dosing",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bicillin&reg; L-A: 600,000 units/mL (1 mL, 2 mL, 4 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F207537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer undiluted as deep I.M. injection in the upper outer quadrant of the buttock (adolescents and adults) or into the midlateral aspect of the thigh (neonates, infants, and children); do",
"     <b>",
"      not",
"     </b>",
"     give I.V., intra-arterially or SubQ;",
"     <b>",
"      inadvertent I.V. administration has resulted in thrombosis, severe neurovascular damage, cardiac arrest, and death",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); avoid freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active against many gram-positive organisms and some spirochetes; treatment of syphilis; used only for the treatment of mild-to-moderate infections (ie,",
"     <i>",
"      Streptococcus",
"     </i>",
"     pharyngitis) caused by organisms susceptible to low concentrations of penicillin G, or for prophylaxis of infections caused by these organisms, such as rheumatic fever disease and acute glomerulonephritis (FDA approved in all ages)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F207616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Penicillin may be confused with penicillamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bicillin&reg; may be confused with Wycillin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Penicillin G benzathine may only be administered by deep intramuscular injection; intravenous administration of penicillin G benzathine has been associated with cardiopulmonary arrest and death.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bicillin&reg; C-R (penicillin G benzathine and penicillin G procaine) may be confused with Bicillin&reg; L-A (penicillin G benzathine). Penicillin G benzathine is the only product currently approved for the treatment of syphilis. Administration of penicillin G benzathine and penicillin G procaine combination instead of Bicillin&reg; L-A may result in inadequate treatment response.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F207613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, cerebral vascular accident, cyanosis, gangrene, hypotension, pallor, palpitations, syncope, tachycardia, vasodilation, vasospasm, vasovagal reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, coma, confusion, dizziness, euphoria, fatigue, headache, nervousness, pain, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     In addition, a syndrome of CNS symptoms has been reported which includes: Severe agitation with confusion, hallucinations (auditory and visual), and fear of death (Hoigne&rsquo;s syndrome); other symptoms include cyanosis, dizziness, palpitations, psychosis, seizures, tachycardia, taste disturbance, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloody stool, intestinal necrosis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, priapism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions: Abscess, atrophy, bruising, cellulitis, edema, hemorrhage, inflammation, lump, necrosis, pain, skin ulcer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthritis exacerbation, joint disorder, neurovascular damage, numbness, periostitis, rhabdomyolysis, transverse myelitis, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blindness, blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, hematuria, myoglobinuria, neurogenic bladder, proteinuria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions, Jarisch-Herxheimer reaction, lymphadenopathy, mottling, warmth",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to penicillin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function, impaired cardiac function, pre-existing seizure disorder, history of significant allergies and/or asthma, or hypersensitivity to cephalosporins. Repeated I.M. injections into anterolateral thigh may result in quadriceps femoris fibrosis or atrophy; risk higher in neonates and infants.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7281655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer I.V.; do not admix with other I.V. solutions; inadvertent I.V. administration has resulted in cardiac arrest and death",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Injection into or near a nerve may result in permanent neurovascular and neurological damage, gangrene requiring amputation of proximal portions of extremities, necrosis, and sloughing at the injection site; effects have most often occurred in infants and small children. Serious hypersensitivity reactions, including anaphylaxis, have been reported; supportive therapy and medication for the management of anaphylactic reactions should be available for immediate use. Superinfection and",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea have been reported with use of penicillin G benzathine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Penicillin crosses the placenta and distributes into amniotic fluid. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects. Penicillin G is the drug of choice for treatment of syphilis during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, urinalysis, culture, renal function tests, stool frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Minimal concentrations attained in CSF with inflamed or uninflamed meninges; highest levels in the kidneys; lesser amounts in liver, skin, intestine; excreted in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 12-24 hours; serum levels are usually detectable for 1-4 weeks depending on the dose; larger doses result in more sustained levels rather than higher levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted by renal tubular excretion; penicillin G is detected in urine for up to 12 weeks after a single I.M. injection; renal clearance is delayed in neonates, young infants, and patients with impaired renal function",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use a penicillin G benzathine/penicillin G procaine combination (ie, Bicillin&reg; C-R) to achieve early peak levels in acute infections. Do not administer Bicillin&reg; C-R to treat patients infected with syphilis since this may result in inadequate treatment.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Sexually Transmitted Diseases Treatment Guidelines - 2006,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-11):1-100. Available at",
"      <a href=\"file://www.cdc.gov/std/treatment/2006/rr5511.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/std/treatment/2006/rr5511.pdf",
"      </a>",
"      .  Accessed September 18, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al, \"Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute",
"      <i>",
"       Streptococcal pharyngitis",
"      </i>",
"      : A Scientific Statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(11):1541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19029/abstract-text/19246689/pubmed\" id=\"19246689\" target=\"_blank\">",
"        19246689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan EL, Berrios X, Speth J, et al, &ldquo;Pharmacokinetics of Benzathine Penicillin G: Serum Levels During the 28 Days After Intramuscular Injection of 1,200,000 Units,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 115(1):146-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19029/abstract-text/2738782 /pubmed\" id=\"2738782 \" target=\"_blank\">",
"        2738782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paryani SG, Vaughn AJ, Crosby M, et al, &ldquo;Treatment of Asymptomatic Congenital Syphilis: Benzathine Versus Procaine Penicillin G Therapy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(3):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19029/abstract-text/ 8071762 /pubmed\" id=\" 8071762 \" target=\"_blank\">",
"        8071762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman ST, Bisno AL, Clegg HW, et al, \"Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2012.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19029/abstract-text/22965026/pubmed\" id=\"22965026\" target=\"_blank\">",
"        22965026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12686 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19029=[""].join("\n");
var outline_f18_37_19029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7272304\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663226\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049222\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444090\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049214\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207553\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207537\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049225\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049218\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049224\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207616\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207613\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049228\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049213\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7281655\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299839\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207546\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207549\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720604\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049221\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049212\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049227\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049229\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12686\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12686|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/50/12070?source=related_link\">",
"      Penicillin G benzathine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/41/44691?source=related_link\">",
"      Penicillin G benzathine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_37_19030="Chlorpheniramine, pseudoephedrine, and dextromethorphan: Drug information";
var content_f18_37_19030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine, pseudoephedrine, and dextromethorphan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/28/22981?source=see_link\">",
"    see \"Chlorpheniramine, pseudoephedrine, and dextromethorphan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dicel&reg; DM Chewables [OTC];",
"     </li>",
"     <li>",
"      Kidkare Children's Cough/Cold [OTC];",
"     </li>",
"     <li>",
"      M-END DM [OTC];",
"     </li>",
"     <li>",
"      Maxichlor PSE DM [OTC] [DSC];",
"     </li>",
"     <li>",
"      Neutrahist PDX [OTC];",
"     </li>",
"     <li>",
"      Pedia Relief&trade; Cough-Cold [OTC];",
"     </li>",
"     <li>",
"      Pediatric Cough &amp; Cold [OTC];",
"     </li>",
"     <li>",
"      Rescon DM [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of cold symptoms:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of chlorpheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorpheniramine 2 mg, pseudoephedrine 15 mg, and dextromethorphan 15 mg per 5 mL: 10 mL every 6 hours (maximum: 40 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorpheniramine 2 mg, pseudoephedrine 30 mg, and dextromethorphan 10 mg per 5 mL: 10 mL every 4-6 hours (maximum:  40 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorpheniramine 4 mg, pseudoephedrine 20 mg, and dextromethorphan 20 mg per 5 mL: 5 mL every 4-6 hours (maximum: 30 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorpheniramine 2 mg, pseudoephedrine 30 mg, and dextromethorphan 10 mg: Two tablets every 4-6 hours (maximum:  8 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chlorpheniramine 4 mg, pseudoephedrine 60 mg, and dextromethorphan 20 mg: One tablet every 4-6 hours (maximum: 4 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F150455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of cold symptoms:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     All dosing is presented in terms of chlorpheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Children 6-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 0.8 mg, pseudoephedrine 9 mg, and dextromethorphan 3 mg per 1 mL: 2 mL every 4-6 hours (maximum: 8 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 1 mg, pseudoephedrine 15 mg, and dextromethorphan 5 mg per 5 mL: 10 mL every 4-6 hours (maximum:  40 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 2 mg, pseudoephedrine 15 mg, and dextromethorphan 15 mg per 5 mL: 5 mL every 6 hours (maximum:  20 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 2 mg, pseudoephedrine 30 mg, and dextromethorphan 10 mg per 5 mL: 5 mL every 4-6 hours (maximum:  20 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 4 mg, pseudoephedrine 20 mg, and dextromethorphan 20 mg per 5 mL: 2.5 mL every 4-6 hours (maximum: 15 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 2 mg, pseudoephedrine 30 mg, and dextromethorphan 10 mg:  One tablet every 4-6 hours (maximum:  4 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chlorpheniramine 4 mg, pseudoephedrine 60 mg, and dextromethorphan 20 mg: One-half tablet every 4-6 hours (maximum: 2 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kidkare Children's Cough/Cold: Chlorpheniramine maleate 1 mg, pseudoephedrine hydrochloride 15 mg, and dextromethorphan hydrobromide 5 mg per 5 mL (118 mL) [ethanol free; contains propylene glycol and sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxichlor PSE DM: Chlorpheniramine maleate 4 mg, pseudoephedrine hydrochloride 20 mg, and dextromethorphan hydrobromide 20 mg per 5 mL (473 mL) [sugar free; contains propylene glycol; vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     M-END DM: Chlorpheniramine maleate 2 mg, pseudoephedrine hydrochloride 15 mg, and dextromethorphan hydrobromide 15 mg per 5 mL (30 mL) [ethanol free, sugar free; contains propylene glycol; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pedia Relief&trade; Cough-Cold: Chlorpheniramine maleate 1 mg, pseudoephedrine hydrochloride 15 mg, and dextromethorphan hydrobromide 5 mg per 5 mL (120 mL) [ethanol free; contains propylene glycol and sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric Cough &amp; Cold: Chlorpheniramine maleate 1 mg, pseudoephedrine hydrochloride 15 mg, and dextromethorphan hydrobromide 5 mg per 5 mL (120 mL) [ethanol free; contains propylene glycol, sodium benzoate; wild cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rescon DM: Chlorpheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg, and dextromethorphan hydrobromide 10 mg per 5 mL (120 mL, 480 mL) [dye free, ethanol free, sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neutrahist PDX: Chlorpheniramine maleate 0.8 mg, pseudoephedrine hydrochloride 9 mg, and dextromethorphan hydrobromide 3 mg per 1 mL (30 mL) [ethanol free, sugar free; contains propylene glycol; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Chlorpheniramine maleate 4 mg, pseudoephedrine hydrochloride 60 mg, and dextromethorphan hydrobromide 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxichlor PSE DM:  Chlorpheniramine maleate 4 mg, pseudoephedrine hydrochloride 60 mg, and dextromethorphan hydrobromide 20 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dicel&reg; DM Chewables: Chlorpheniramine maleate 2 mg, pseudoephedrine hydrochloride 30 mg, and dextromethorphan hydrobromide 10 mg [ethanol free; contains sodium 19 mg/tablet, soy lecithin; cotton candy flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Liquid, tablet",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporarily relieves nasal congestion, runny nose, cough, and sneezing due to the common cold, hay fever, or allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F150439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chlorpheniramine, pseudoephedrine, dextromethorphan, or any component of the formulation; use with or within 2 weeks of discontinuing MAO inhibitor",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F150427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with asthma or other chronic breathing disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children. Not labeled for OTC use in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. Discontinue and contact healthcare provider if nervousness, dizziness, or sleeplessness occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13842272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F150441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Dicel DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-2-10 mg (20): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Rescon DM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30-2-10 mg/5 mL (120 mL): $10.56",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F150426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chlorpheniramine competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. Dexchlorpheniramine is the predominant active isomer of chlorpheniramine and is approximately twice as active as the racemic compound.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pseudoephedrine is a sympathomimetic amine and isomer of ephedrine; acts as a decongestant in respiratory tract mucous membranes with less vasoconstrictor action than ephedrine in normotensive individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dextromethorphan is a chemical relative of morphine lacking narcotic properties except in overdose; controls cough by depressing the medullary cough center.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19030/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9257 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-422ACB6E1F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19030=[""].join("\n");
var outline_f18_37_19030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150449\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150458\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150450\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150455\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062974\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150434\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150425\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150436\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150456\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150439\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150427\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299031\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150430\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150447\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13842272\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150441\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150426\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150438\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9257|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/28/22981?source=related_link\">",
"      Chlorpheniramine, pseudoephedrine, and dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_37_19031="Synthetic conjugated estrogens B: Drug information";
var content_f18_37_19031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Synthetic conjugated estrogens B: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/20/42309?source=see_link\">",
"    see \"Synthetic conjugated estrogens B: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2973872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enjuvia&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2973306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Estrogen Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2973339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The lowest dose that will control symptoms should be used. Medication should be discontinued as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Menopause, moderate-to-severe vasomotor symptoms: Oral: 0.3 mg/day; may be titrated up to 1.25 mg/day. Attempts to discontinue medication should be made at 3- to 6-month intervals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal dryness/vulvar and vaginal atrophy associated with menopause: Oral: 0.3 mg/day. Attempts to discontinue medication should be made at 3- to 6-month intervals.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2973340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. A higher incidence of stroke and invasive breast cancer were observed in women &gt;75 years in a WHI substudy using conjugated equine estrogen.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2973348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enjuvia&trade;: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2973304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16360842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2973309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderate-to-severe vasomotor symptoms of menopause; treatment of vulvar and vaginal atrophy associated with menopause; treatment of moderate-to-severe vaginal dryness and pain with intercourse associated with menopause",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Enjuvia&trade; may be confused with Januvia&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2973318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (15% to 25%), pain (10% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (up to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (4% to 15%), nausea (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (1% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (1% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (2% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (up to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (up to 7%), rhinitis (4% to 7%), sinusitis (3% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     In addition, the following have been reported with estrogen and/or progestin therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, hypertension, MI, stroke, venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Epilepsy exacerbation, irritability, mental depression, migraine, mood disturbances, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Angioedema, chloasma, erythema multiforme, erythema nodosum, hemorrhagic eruption, hirsutism, loss of scalp hair, melasma, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast cancer, breast enlargement, breast tenderness, HDL-cholesterol increased, hyper-/hypocalcemia, impaired glucose tolerance, LDL-cholesterol decreased, libido (changes in), serum triglycerides/phospholipids increased, thyroid-binding globulin increased, total thyroid hormone (T",
"     <sub>",
"      4",
"     </sub>",
"     ) increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, bloating, cholecystitis, cholelithiasis, gallbladder disease, pancreatitis, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Alterations in frequency and flow of menses, changes in cervical secretions, endometrial cancer, endometrial hyperplasia, increased size of uterine leiomyomata, vaginal candidiasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Aggravation of porphyria; antithrombin III and antifactor Xa decreased; fibrinogen levels increased; platelet aggregability and platelet count increased; prothrombin and factors VII, VIII, IX, X increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic hemangiomas enlarged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgias, chorea, leg cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature steepening, retinal vascular thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma exacerbation, pulmonary thromboembolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid/anaphylactic reactions, carbohydrate intolerance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2973313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to estrogens or any component of the formulation; undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT, PE); active or recent (within 1 year) arterial thromboembolic disease (eg, stroke, MI); carcinoma of the breast; estrogen-dependent tumor; hepatic dysfunction or disease; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2973314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may also lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use caution with migraine; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE; may exacerbate disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of oral estrogen (with or without progestins) in this age group due to potential of increased risk of breast and endometrial cancers, and lack of proven cardioprotection and cognitive protection (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children. Prior to puberty, estrogens may cause premature closure of the epiphyses, premature breast development in girls or gynecomastia in boys. Vaginal bleeding and vaginal cornification may also be induced in girls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, estrogens should be discontinued at least 4-6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal dryness/atrophy: When used solely for the treatment of vaginal dryness and pain with intercourse, or vulvar and vaginal atrophy, topical vaginal products should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2973324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2973323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: Estrogen Derivatives may diminish the therapeutic effect of Somatropin. Shown to be a concern with oral hormone replacement therapy in postmenopausal women.  Management: Monitor for reduced growth hormone efficacy. A larger somatropin dose may be required to reach treatment goal.  This interaction does not appear to apply to non-orally administered estrogens (e.g., transdermal, vaginal ring).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2973327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (routine use increases estrogen plasma concentrations and risk of breast cancer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may increase estrogen plasma concentrations, leading to increased adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, and yucca.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2973310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use during pregnancy is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2973311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2973312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Estrogen has been shown to decrease the quantity and quality of human milk. Use only if clearly needed. Monitor the growth of the infant closely.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Enjuvia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (100): $249.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.45 mg (100): $249.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.625 mg (100): $249.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.9 mg (100): $249.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (100): $249.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2973341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yearly physical examination that may include blood pressure and Papanicolaou smear, breast exam, mammogram. Monitor for signs of endometrial cancer in female patients with uterus. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Monitor for loss of vision, sudden onset of proptosis, diplopia, migraine; signs and symptoms of thromboembolic disorders; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2973332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conjugated B/synthetic estrogens contain a mixture of 10 synthetic estrogen substances, including sodium estrone sulfate, sodium equilin sulfate, sodium 17-alpha-dihydroequilin, sodium 17-alpha-estradiol, and sodium 17-beta-dihydroequilin. Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principle intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2973333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed over a period of several hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: Sex hormone-binding globulin (SHBG) and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; estradiol is converted to estrone and estriol; also undergoes enterohepatic recirculation; estrone sulfate is the main metabolite in postmenopausal women",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Conjugated estrone: 8-20 hours; conjugated equilin: 5-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily estriol, also as estradiol, estrone, and conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grodstein F, Stampfer MJ, Colditz GA, et al, &ldquo;Postmenopausal Hormone Therapy and Mortality,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(25):1769-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/9187066/pubmed\" id=\"9187066\" target=\"_blank\">",
"        9187066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hulley S, Grady D, Bush T, et al, &ldquo;Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 280(7):605-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/9718051/pubmed\" id=\"9718051\" target=\"_blank\">",
"        9718051",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/37/19031/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9503 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-7288C09AE7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19031=[""].join("\n");
var outline_f18_37_19031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708754\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973872\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973306\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973339\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973340\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973348\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973304\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16360842\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973309\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914298\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973318\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973313\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973314\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973324\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973327\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973310\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973311\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973312\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422181\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973341\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973332\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2973333\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9503\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9503|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/20/42309?source=related_link\">",
"      Synthetic conjugated estrogens B: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_37_19032="Sonogram complete mole";
var content_f18_37_19032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66877%7EOBGYN%2F57523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66877%7EOBGYN%2F57523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sonogram of a complete hydatidiform mole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fetus is absent and the hydropic vesicle changes of the trophoblast have the typical grapelike appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beryl Benacerraf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound complete hydatid mole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 530px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Complete hydatidiform mole: Ultrasound shows a 20 week size uterus. The endometrial cavity is filled with vesicular echogenic material. No fetus is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Department of Radiology, Santa Clara Valley Medical Center.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19032=[""].join("\n");
var outline_f18_37_19032=null;
var title_f18_37_19033="Pathogenesis of Salmonella gastroenteritis";
var content_f18_37_19033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of Salmonella gastroenteritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/37/19033/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19033/contributors\">",
"     Camille N Kotton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19033/contributors\">",
"     Elizabeth L Hohmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/37/19033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19033/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/37/19033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19033/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/37/19033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salmonellae cause a broad range of infections, including gastroenteritis, enteric fever, bacteremia, endovascular infections, and focal infections such as osteomyelitis and abscesses. Salmonellae are facultative anaerobic gram-negative bacilli and usually enter the body via the gastrointestinal (GI) tract, where they can persist for long periods of time. Salmonellae can act as both commensals and pathogens and are found in the GI tracts of domestic and wild animals, including insects, reptiles, birds, and mammals.",
"   </p>",
"   <p>",
"    Although there are many types of Salmonella, they can be divided into two broad categories: those that cause typhoid and enteric fever and those that primarily induce gastroenteritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The typhoidal Salmonella, such as S. typhi or S. paratyphi primarily colonize humans, are transmitted via the consumption of fecally contaminated food or water, and cause a systemic illness usually with little or no diarrhea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"       \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The much broader group of nontyphoidal Salmonella usually results from improperly handled food that has been contaminated by animal or human fecal material. It can also be acquired via the fecal-oral route, either from other humans or farm or pet animals [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"       \"Microbiology and epidemiology of salmonellosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The bacterial and host factors that contribute to Salmonella gastroenteritis will be reviewed here (",
"    <a class=\"graphic graphic_figure graphicRef80734 \" href=\"UTD.htm?36/7/36984\">",
"     figure 1",
"    </a>",
"    ). The approach to patients with Salmonella in a stool culture is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different serovars of Salmonella cause human infection. The source of infection typically is from food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Serotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2000-plus serovars of Salmonella can be characterized by three major antigens: the somatic O antigen, which is derived from the LPS cell wall component; the flagellar H antigen, and the surface Vi antigen. The O-antigen is widely used by clinical laboratories to divide Salmonella into serogroups A, B, C1, C2, D, and E (",
"    <a class=\"graphic graphic_table graphicRef81462 \" href=\"UTD.htm?4/6/4204\">",
"     table 1",
"    </a>",
"    ). Significant cross-reactivity can occur between serogroups. The serogroups cannot be used to divide enteric fever-causing strains from gastroenteritis-causing strains: group D contains both S. enteritidis and S. typhi, while group B contains S. typhimurium as well as some strains of S. paratyphi. To investigate a possible outbreak, further identification must be done with bacteriophage typing, restriction fragment length polymorphism analysis, pulsed-field gel electrophoresis, and plasmid profile determination.",
"   </p>",
"   <p>",
"    The host specificity of different Salmonella serotypes often determines the nature of the clinical illness. Classic typhoid or enteric fever is caused by Salmonella typhi and Salmonella paratyphi. These strains are highly adapted for humans and do not colonize or cause disease in animals, though S. paratyphi has very rarely been associated with domestic animals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=see_link\">",
"     \"Pathogenesis of typhoid fever\"",
"    </a>",
"    .) Those serotypes which cause enteric fever are frequently not associated with significant diarrheal symptoms, although enteric fever may be heralded by transient diarrhea prior to the onset of fever.",
"   </p>",
"   <p>",
"    Salmonella enteritidis and Salmonella typhimurium have broad host ranges and may produce colonization or gastroenteritis in humans, mice, and fowl. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"     \"Microbiology and epidemiology of salmonellosis\"",
"    </a>",
"    .) These serotypes are most frequently associated with gastroenteritis in humans because of the large reservoirs of bacteria in domestic animals. Salmonella choleraesuis (adapted for swine) and Salmonella dublin (adapted for cattle) are associated with human septicemia and metastatic foci of infection but are uncommon causes of gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/2\">",
"     2",
"    </a>",
"    ]. Salmonella gallinarum-pullorum (adapted for fowl) causes relatively transient illness in humans only after very large inocula are ingested. The molecular bases of these species specificities is complex and currently under investigation.",
"   </p>",
"   <p>",
"    The epidemiology of Salmonella has evolved over time. During the 2000s, the incidence of Salmonella typhimurium decreased, while serotypes Newport, Mississippi, and Javiana increased in incidence. Specific control programs focusing on contaminated eggs might have led to the reduction of S. enteritidis infections. Rates of antibiotic resistance among several serotypes have been increasing and are an area of significant concern; a substantial proportion of S. typhimurium and S. newport isolates are multi-drug resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sources of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are an estimated two to four million cases of Salmonellosis per year in the United States, with gastroenteritis as the most common clinical presentation. Nontyphoidal Salmonella account for 9.7 percent of all bacterial foodborne illnesses and 30.6 percent of deaths as of 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/4\">",
"     4",
"    </a>",
"    ]; between the time periods 1996 to 1998 and 2005, the number of Salmonella cases decreased by 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/5\">",
"     5",
"    </a>",
"    ]. Salmonella gastroenteritis usually results from improperly handled food. It can also be acquired via the fecal-oral route, either from other humans or farm or pet animals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=see_link\">",
"     \"Differential diagnosis of microbial foodborne disease\"",
"    </a>",
"    .) In the United States, serotypes Typhimurium, Enteritidis, and Newport are the most common serotypes. During 2006, large multistate outbreaks of Salmonellosis were linked to consumption of tomatoes, fruit salad, pet turtles, and peanut butter [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is estimated that 1 in 10,000 egg yolks is infected with Salmonella enteritidis. In 1976, there were 0.6 cases of Salmonella enteritidis per 100,000; by 1996 there were 3.6 cases per 100,000, with the majority of the increase due to eggs. A recent risk assessment model for Salmonella enteritidis infection in eggs estimates that of the approximately 69 billion eggs produced annually, 2.3 million would be contaminated with Salmonella enteritidis and that an average of 661,633 human illnesses would develop from their consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/6\">",
"     6",
"    </a>",
"    ]. An estimated 94 percent of these cases recover without medical care, 5 percent visit a physician, an additional 0.5 percent are hospitalized, and 0.05 percent result in death.",
"   </p>",
"   <p>",
"    A multistate outbreak of S. newport from imported mangos was felt to be related to hot water treatment of the fruit to prevent importation of the Mediterranean fruit fly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/7\">",
"     7",
"    </a>",
"    ]. While fruit skin usually acts as a physical barrier to pathogens, the heating and cooling of the fruit may have created an inward hydrostatic force that allowed for the entry of S. newport. There have been numerous other outbreaks, some of which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"     \"Microbiology and epidemiology of salmonellosis\"",
"    </a>",
"    .) The incidence of salmonellosis is highest during the summer in temperate climates (eg, from May to October in the Northern hemisphere) and during the rainy season in tropical climates, which coincides with the peak in foodborne outbreaks.",
"   </p>",
"   <p>",
"    Exotic pets may be a source of salmonellosis. Approximately 90 percent of reptiles carry Salmonella. Cases of salmonellosis in infants have been reported in households in which iguanas, bearded dragons, or snakes were handled by adults with probable subsequent spread to the children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/8\">",
"     8",
"    </a>",
"    ]. An estimated 3 to 5 percent of all cases of salmonellosis in humans is due to exposure to pets, including turtles, birds, rodents, dogs, and cats. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=see_link\">",
"     \"Zoonoses from dogs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=see_link\">",
"     \"Zoonoses from cats\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=see_link\">",
"     \"Zoonoses from pets other than dogs and cats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infectious dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the number of Salmonella organisms required for clinical illness have been obtained from studies on human volunteers and outbreaks in which the vehicle of inoculation was quantitatively cultured [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/9\">",
"     9",
"    </a>",
"    ]. Several general statements about infectious doses can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large inocula (&gt;10(4)) produce higher rates of illness after shorter incubation periods than small inocula (&le;10(3)).",
"     </li>",
"     <li>",
"      Asymptomatic excretion may occur after ingestion of small inocula, although even very small inocula (5 to 100 organisms) may cause disease in susceptible hosts.",
"     </li>",
"     <li>",
"      Antibiotic use can reduce the infectious dose necessary to cause disease by diminishing the normally protective indigenous flora (see below).",
"     </li>",
"     <li>",
"      The infectious dose is lower in patients with clinical conditions associated with a reduction in gastric acidity such as neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/10\">",
"       10",
"      </a>",
"      ], achlorhydric states [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/11\">",
"       11",
"      </a>",
"      ], gastric surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/12,13\">",
"       12,13",
"      </a>",
"      ] and the use of antacids or H2 blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Water supplies are contaminated at lower levels than food, resulting in lower attack rates and longer incubation periods in waterborne outbreaks.",
"     </li>",
"     <li>",
"      Salmonella may persist for months in cheese, frozen meat, or ice cream.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors related both to the pathogen and the host influence the pathogenesis of Salmonella gastroenteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interaction of Salmonellae with enteric host defenses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingested microorganisms must traverse the acidic barrier of the stomach in order to establish enteric infection (",
"    <a class=\"graphic graphic_table graphicRef51300 \" href=\"UTD.htm?24/18/24875\">",
"     table 2",
"    </a>",
"    ). Although Salmonella and other enteric pathogens survive poorly at the very low pH encountered in the stomach, Salmonella exhibit increased tolerance to \"acid shock\" if first exposed to a moderately acidic environment (pH 4 to 5). The organism's ability to adapt to low pH has been called the acid tolerance response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salmonellae that survive passage through the stomach must then compete with the normal intestinal microbial flora. The indigenous flora is an important but often overlooked barrier to infection with enteric pathogens. Elegant mouse studies performed in the 1960s showed that a single injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    reduced the oral infectious dose of Salmonella typhimurium by over 100,000-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/16\">",
"     16",
"    </a>",
"    ]. Studies in animals have shown that the protective effect of indigenous microbes is due to a variety of factors including competition for nutrients, maintenance of a low luminal pH, and production of inhibitory compounds such as volatile fatty acids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings appear to be applicable to humans, as can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylactic antimicrobial therapy increases the frequency of salmonellosis among travelers [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients found to be infected during an outbreak of multidrug resistant Salmonella typhimurium enteritis used antimicrobials in the month before the onset of illness much more frequently than controls (30 versus 6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/20\">",
"       20",
"      </a>",
"      ]. A similar association with prior antimicrobial use was noted in a multistate outbreak of illness caused by Salmonella havana which was pansensitive to antimicrobial agents (30 versus 13 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/21\">",
"       21",
"      </a>",
"      ]. The association persisted even when controlled for the presence of underlying illness or immunosuppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    S. Typhimurium has a marked and unique growth advantage over other bacteria when using a specific nutrient, ethanolamine, which is released from host tissue in the lumen of the inflamed intestine and is not utilizable by competing bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, by inducing intestinal inflammation, S. Typhimurium sidesteps nutritional competition and creates a significant survival advantage for itself.",
"   </p>",
"   <p>",
"    In addition to competition from the indigenous bacterial flora, Salmonella must withstand a gamut of enteric defenses including bile salts, pancreatic enzymes, Paneth cell antimicrobial peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/23\">",
"     23",
"    </a>",
"    ], and secretory IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mechanisms of adherence and invasion",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two main components to Salmonella infection of the GI tract: adherence and subsequent invasion. Adherence is complex and is mediated by multiple genes. Fimbriae are very important in adhering to and adapting to a eukaryotic cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/25\">",
"     25",
"    </a>",
"    ]; several fimbrial operons may facilitate adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/26\">",
"     26",
"    </a>",
"    ]. Biofilms may play a role as well [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/25\">",
"     25",
"    </a>",
"    ]. The invasion operon (inv) can also induce adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Invasion may be achieved by several different mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salmonella can selectively attach to specialized epithelial cells overlying Peyer's patches in the colon known as M (microfold) cells. These cells are an important portal of entry of Salmonellae and other pathogens into the submucosal lymphoid system [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/28\">",
"       28",
"      </a>",
"      ]. M cells are highly endocytic and can rapidly transfer material from their luminal side to their basal side, where the T cells and antigen-presenting cells reside, ready to elicit an immune response.",
"     </li>",
"     <li>",
"      It has been suggested that the cells of the columnar epithelium may also be an important common portal of entry for Salmonella, particularly since they greatly outnumber the M cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Salmonellae can also induce nonphagocytic cells such as enterocytes to internalize them. This process of bacterial-mediated endocytosis has been extensively studied in vitro and appears to be important in the pathogenesis of Salmonella gastroenteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Invasion can also occur via the dendritic cells that intercalate between epithelial cells by extending protrusions into the gut lumen.",
"     </li>",
"     <li>",
"      Numerous small foci of solitary intestinal lymphoid tissues (SILTs) with a strong inflammatory response can be found in the murine small intestine; Salmonella can be observed within these SILTs at early stages of infection, and the SILTs may act as portals of entry [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following invasion into the cell, the bacteria remain within a modified phagosome known as the Salmonella-containing vacuole (SCV), within which they will survive and replicate. Type III secretion systems are used to translocate bacterial effector proteins into the host cell, mediating both invasion and vacuole biogenesis. Vacuole biogenesis is a complex and dynamic process involving extensive membrane remodeling, interactions with the endolysosomal pathway, actin rearrangements, and microtubule-based movement and tubule extension [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms of persistent Salmonella fecal shedding of Salmonella are under investigation. The shdA gene, which encodes an outer membrane autotransporter protein that binds fibronectin, is required for persistent shedding of Salmonella typhimurium in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/34\">",
"     34",
"    </a>",
"    ]. This raises the question of whether this locus might mediate adherence of Salmonella at other clinically important structures known to be foci of metastatic infection, such as arteries and bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathogenicity islands",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two Salmonella \"pathogenicity islands\" (SPI) have been found, termed SPI-1 and 2, each about 40 kilobases of DNA and located at centrosomes 63 and 30 of the chromosome, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/35-40\">",
"     35-40",
"    </a>",
"    ]. Both SPIs encode multiple virulence factors, including Type III secretions systems (TTSS). The TTSS creates a hypodermic needle-like apparatus (",
"    <a class=\"graphic graphic_figure graphicRef69640 \" href=\"UTD.htm?24/23/24959\">",
"     figure 2",
"    </a>",
"    ) and injects proteins into the cells, facilitating uptake of the bacteria into those cells. SPI-1 encodes genes needed for nonphagocytic cell invasion via a ruffling mechanism and initiation of intestinal secretory and inflammatory responses. SPI-2 is induced within the cell and contains genes needed for survival and replication within macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/41\">",
"     41",
"    </a>",
"    ]. Some of these genes induce secretory and inflammatory responses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Some of these genes on SPI-1 encode proteins homologous to Shigella proteins which direct the export and translocation of signaling molecules capable of interacting with eukaryotic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The secreted proteins of both Salmonella and Shigella induce ruffled projections in eukaryotic cell membranes which subsequently invaginate and internalize the invading bacterium within a membrane bound vacuole, called macropinocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=see_link&amp;anchor=H440124159#H440124159\">",
"     \"Epidemiology, microbiology, and pathogenesis of Shigella infection\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutants lacking these genes display reduced virulence. In one study avirulent environmental isolates of S. senftenberg and S. litchfield contained deletions in SPI-1, while clinical isolates of the same serotypes retained the gene cluster [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inflammatory response mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to facilitating their own uptake, virulent strains of Salmonella are able to induce migration of subepithelial neutrophils across polarized epithelial cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/46\">",
"     46",
"    </a>",
"    ]. A substantial neutrophil infiltration into the intestine occurs in Salmonella typhimurium-induced colitis in humans; whether this is due to effectors from Salmonella or innate pathways of inflammation triggered by pathogen recognition receptors on cells in the lamina propria is a matter of debate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/47\">",
"     47",
"    </a>",
"    ]. The paracellular traffic of neutrophils has been hypothesized to induce diarrhea by causing paracellular fluid and electrolyte fluxes. This theory is supported by the observation that strains which do not usually cause enteritis, such as S. typhi and S. gallinarum, also do not induce neutrophil transmigration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to IL-8, Salmonella induce other proinflammatory cytokines such as GM-CSF, monocyte chemotactic protein-1, and tumor necrosis factor-alpha in colonic epithelial cells, which in turn mediate further immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/49\">",
"     49",
"    </a>",
"    ]. Macrophages respond to S. typhimurium infection via flagellin-mediated activation of Ipaf, a NACHT-leucine-rich repeat family member that activates caspase-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/50\">",
"     50",
"    </a>",
"    ]. Activated caspase-1 is required for the secretion of proinflammatory cytokines, such as interleukin (IL)-1beta and IL-18, and is important in host defense against a variety of pathogens; caspase-1-deficient mice are more susceptible to several pathogens including, Shigella, Listeria and Francisella tularensis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/51-53\">",
"     51-53",
"    </a>",
"    ], as well as Salmonella [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lipid A is the biologically active component of lipopolysaccharide (LPS) found in the cell wall of Salmonella and other gram-negative bacteria. Lipid A is toxic to mammalian cells and is a potent immunomodulator. Certain features of the lipid A in Salmonella may correlate with virulence or with activation of host inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Lipid A induces toll-like receptor 4 (TLR4)-mediated responses, which are important for host defense against Salmonella infection, and modifications in lipid A as part of Salmonella's adaptation to host environments reduce this signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/57\">",
"     57",
"    </a>",
"    ]. Death in mice from Salmonella may be related to the toxic effect of lipid A, which triggers further production of TNF-alpha and IL-1 beta. S. typhimurium mutants with a defective lipid A molecule have greatly attenuated virulence in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/58\">",
"     58",
"    </a>",
"    ]. Structural modifications of lipid A are influenced by the Salmonella virulence regulatory locus",
"    <span class=\"nowrap\">",
"     (phoP/phoQ)",
"    </span>",
"    which responds to a variety of host intracellular environmental signals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/59\">",
"     59",
"    </a>",
"    ]. For example, antimicrobial peptides have been shown to be part of the first step in signal transduction across the bacterial membrane, resulting in activation of phoQ and promotion of bacterial virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/60\">",
"     60",
"    </a>",
"    ]. PhoP has also been found to bind a promoter region of a drug efflux system, thus connecting virulence with possible drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enterotoxins may also play a role in Salmonella gastroenteritis. An enterotoxin, encoded by the stn gene and antigenically similar to cholera toxin has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. While many Salmonellae carry the stn gene, only a fraction express the gene, as assessed by CHO cell assay [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/65\">",
"     65",
"    </a>",
"    ]. Additional characterization of the enterotoxin is needed to assess its role in human pathogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Survival within phagocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salmonellae have long been known to persist within the reticuloendothelial system. Macrophages may be the main cell type to support bacterial growth in vivo, and this growth is regulated by both the host and the Salmonella [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/66\">",
"     66",
"    </a>",
"    ]. The ability of Salmonella to survive within macrophages contributes to the dissemination of the microorganism from the submucosa to the circulation and the reticuloendothelial system. Intracellular bacterial growth within phagocytes is limited by mechanisms requiring reactive oxygen intermediates, reactive nitrogen intermediates, lysosomal enzymes, and defensins. Both the",
"    <span class=\"nowrap\">",
"     phoP/phoQ",
"    </span>",
"    virulence regulatory locus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/67-69\">",
"     67-69",
"    </a>",
"    ] and the SPI-2 contain genes that are important for survival within macrophages. The importance of this process is illustrated by studies that showed that",
"    <span class=\"nowrap\">",
"     phoP/phoQ-deleted",
"    </span>",
"    S. typhimurium, when used as a vaccine vector, caused no bacteremia or late sequelae in a limited number of subjects who received a large oral inoculum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/70\">",
"     70",
"    </a>",
"    ]. Isolates of Salmonella typhimurium that are unable to survive within macrophages in vitro are avirulent in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Role of virulence plasmids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontyphoidal Salmonellae also carry a variety of virulence plasmids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/72\">",
"     72",
"    </a>",
"    ]. A highly conserved 8 kilobase region of DNA contained within these plasmids has been associated with the ability of strains to induce bacteremia and persist within the reticuloendothelial system [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. S. typhimurium has a self-transmissible [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/74\">",
"     74",
"    </a>",
"    ] 90 kilobase virulence plasmid that contains the genes spvRABCD and while it increases the growth rate of Salmonellae in macrophages, it may have a limited contribution to virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/75\">",
"     75",
"    </a>",
"    ]. The virulence plasmid stimulates IL-12 production in a mouse model, which may lead to attenuated T cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immune response to Salmonella infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the frequency and nonspecific nature of the symptoms of Salmonella gastroenteritis, little is known about the rates of reinfection and correlates of immunity. The innate immune system, cell-mediated immunity, and humoral immunity all play important roles in limiting Salmonella infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Innate immune system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The innate immune system plays a critical role in the initial response to Salmonella infection. It may be the determining factor in whether the infection is subclinical or more aggressive. The importance of macrophages and polymorphonuclear (PMN) leukocyte response to Salmonella has been well described. Neutropenic mice have a high mortality in experimental Salmonella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/77\">",
"     77",
"    </a>",
"    ], and depressed PMN function increases the incidence of Salmonella infection in humans. These conditions most commonly include sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/78\">",
"     78",
"    </a>",
"    ], malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/79,80\">",
"     79,80",
"    </a>",
"    ], schistosomiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/81\">",
"     81",
"    </a>",
"    ], and histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/82\">",
"     82",
"    </a>",
"    ]. In addition, Toll receptor agonists such as LPS, lipoprotein, and flagellin stimulate proinflammatory cytokine production, resulting in TNF-alpha and interleukin responses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/29\">",
"     29",
"    </a>",
"    ]. Activation of Toll-like receptor 5 and Ipaf by Salmonella flagellin has been a significant finding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cell-mediated immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell-mediated immunity plays an important role in clearing infection and protecting against subsequent Salmonella infection. Clinical vigilance in the diagnosis and management of Salmonella infections should be increased in settings associated with cellular immunosuppression. As an example, infection is more severe and prolonged in patients with depressed cellular immunity due to glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/84\">",
"     84",
"    </a>",
"    ], AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/85-87\">",
"     85-87",
"    </a>",
"    ], and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/88\">",
"     88",
"    </a>",
"    ]. In one study, nontyphoidal Salmonella (14 percent) were the second most frequent bacterial isolate after Staphylococcus aureus (29 percent) in a study of 249 bacteremias in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/89\">",
"     89",
"    </a>",
"    ]. Nude mice and mice deficient in alpha-beta T cells are more susceptible to Salmonella infections. Murine models suggest that CD4+ T cells are more contributory than CD8+ T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Humoral immune responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The humoral response to Salmonella infection is complex and may be protective or maladaptive. Its importance in containing Salmonella infection is illustrated by the protective immunity induced in vaccination studies with S. typhi. Mice deficient in B cells due to a targeted deletion of the Ig-mu gene show increased susceptibility to Salmonella infection and are unable to mount a significant convalescent immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/90\">",
"     90",
"    </a>",
"    ]. In addition, mucosal humoral immune responses may play a contributory role. Murine studies have shown that secretion of large amounts of a single monoclonal IgA directed against Salmonella typhimurium lipopolysaccharide (LPS) into the intestinal lumen provides significant protection against systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, mucosal antibodies to nontyphoidal Salmonellae appear to inhibit the \"take\" of the oral live attenuated typhoid fever vaccine Ty21a [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in a study that evaluated the effect of serum from HIV-infected patients on the killing of S. typhimurium in vitro, a high serum concentration of antibodies against the LPS of non-typhoidal Salmonellae paradoxically prevented the destruction of Salmonella [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19033/abstract/92\">",
"     92",
"    </a>",
"    ]. The authors postulated that inhibitory antibodies in the serum of HIV-infected individuals could be responsible for this effect by blocking the action of bactericidal antibodies. These results suggest that the preferred vaccine target should be the bacterial outer-membrane proteins of non-typhoidal Salmonellae as opposed to LPS, since LPS could potentially elicit inhibitory rather than the desired bactericidal antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/31/27122?source=see_link\">",
"       \"Patient information: Salmonellosis (Salmonella) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4395261\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2000-plus serovars of Salmonella can be characterized by three major antigens: the somatic O antigen, which is derived from the lipopolysaccharide cell wall component, the flagellar H antigen, and the surface Vi antigen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Serotypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The size of the inoculum is proportional to the frequency and rapidity of disease onset, but even small inocula can cause disease. Enteric host factors that defend against Salmonella infection include the acidic environment of the stomach and the normal intestinal microbial flora. The infectious dose necessary to cause disease can be lower in settings of antibiotic use and reduction of gastric acid. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Infectious dose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Interaction of Salmonellae with enteric host defenses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Salmonellae adhere to and invade the gastrointestinal tract and submucosal lymphoid system through several different mechanisms. Bacterial entry into and survival within host cells are facilitated by multiple virulence factors. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mechanisms of adherence and invasion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathogenicity islands'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ability of Salmonella to survive within macrophages contributes to the dissemination of the microorganism from the submucosa to the circulation and the reticuloendothelial system. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Survival within phagocytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virulent strains of Salmonella induce multiple host inflammatory responses and cytokines. This is in part mediated by lipid A, a component of lipopolysaccharide in the cell wall. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Inflammatory response mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The host innate immune response may determine whether Salmonella infection is subclinical or more aggressive. Adaptive cell-mediated immunity plays an important role in clearing and protecting against subsequent infection. The humoral response is complex and may be protective or maladaptive. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Immune response to Salmonella infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/1\">",
"      Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001; 32:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/2\">",
"      Blaser MJ, Feldman RA. From the centers for disease control. Salmonella bacteremia: reports to the Centers for Disease Control, 1968-1979. J Infect Dis 1981; 143:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/3\">",
"      McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases--United States, 2006. MMWR Morb Mortal Wkly Rep 2008; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/4\">",
"      Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. Emerg Infect Dis 1999; 5:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 States, United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/6\">",
"      Hope BK, Baker R, Edel ED, et al. An overview of the Salmonella enteritidis risk assessment for shell eggs and egg products. Risk Anal 2002; 22:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/7\">",
"      Sivapalasingam S, Barrett E, Kimura A, et al. A multistate outbreak of Salmonella enterica Serotype Newport infection linked to mango consumption: impact of water-dip disinfestation technology. Clin Infect Dis 2003; 37:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Reptile-associated salmonellosis--selected states, 1998-2002. MMWR Morb Mortal Wkly Rep 2003; 52:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/9\">",
"      Blaser MJ, Newman LS. A review of human salmonellosis: I. Infective dose. Rev Infect Dis 1982; 4:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/10\">",
"      Agunod M, Yamaguchi N, Lopez R, et al. Correlative study of hydrochloric acid, pepsin, and intrinsic factor secretion in newborns and infants. Am J Dig Dis 1969; 14:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/11\">",
"      Riley LW, Cohen ML, Seals JE, et al. Importance of host factors in human salmonellosis caused by multiresistant strains of Salmonella. J Infect Dis 1984; 149:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/12\">",
"      KUNZ LJ, WADDELL WR. Association of Salmonella enteritis with operations on the stomach. N Engl J Med 1956; 255:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/13\">",
"      Neal KR, Briji SO, Slack RC, et al. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ 1994; 308:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/14\">",
"      Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut 1972; 13:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/15\">",
"      Foster JW. Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Crit Rev Microbiol 1995; 21:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/16\">",
"      BOHNHOFF M, MILLER CP, MARTIN WR. RESISTANCE OF THE MOUSE'S INTESTINAL TRACT TO EXPERIMENTAL SALMONELLA INFECTION. I. FACTORS WHICH INTERFERE WITH THE INITIATION OF INFECTION BY ORAL INOCULATION. J Exp Med 1964; 120:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/17\">",
"      Que JU, Casey SW, Hentges DJ. Factors responsible for increased susceptibility of mice to intestinal colonization after treatment with streptomycin. Infect Immun 1986; 53:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/18\">",
"      Tannock GW, Savage DC. Indigenous microorganisms prevent reduction in cecal size induced by Salmonella typhimurium in vaccinated gnotobiotic mice. Infect Immun 1976; 13:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/19\">",
"      Mentzing LO, Ringertz O. Salmonella infection in tourists. 2. Prophylaxis against salmonellosis. Acta Pathol Microbiol Scand 1968; 74:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/20\">",
"      Ryan CA, Nickels MK, Hargrett-Bean NT, et al. Massive outbreak of antimicrobial-resistant salmonellosis traced to pasteurized milk. JAMA 1987; 258:3269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/21\">",
"      Pavia AT, Shipman LD, Wells JG, et al. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella. J Infect Dis 1990; 161:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/22\">",
"      Thiennimitr P, Winter SE, Winter MG, et al. Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota. Proc Natl Acad Sci U S A 2011; 108:17480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/23\">",
"      Selsted ME, Miller SI, Henschen AH, Ouellette AJ. Enteric defensins: antibiotic peptide components of intestinal host defense. J Cell Biol 1992; 118:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/24\">",
"      Michetti P, Mahan MJ, Slauch JM, et al. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect Immun 1992; 60:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/25\">",
"      Ledeboer NA, Frye JG, McClelland M, Jones BD. Salmonella enterica serovar Typhimurium requires the Lpf, Pef, and Tafi fimbriae for biofilm formation on HEp-2 tissue culture cells and chicken intestinal epithelium. Infect Immun 2006; 74:3156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/26\">",
"      Weening EH, Barker JD, Laarakker MC, et al. The Salmonella enterica serotype Typhimurium lpf, bcf, stb, stc, std, and sth fimbrial operons are required for intestinal persistence in mice. Infect Immun 2005; 73:3358.",
"     </a>",
"    </li>",
"    <li>",
"     Cellular Microbiology, Cossart P, Boquet P, Normark S, Rappuoli R (Eds), ASM Press, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/28\">",
"      Kohbata S, Yokoyama H, Yabuuchi E. Cytopathogenic effect of Salmonella typhi GIFU 10007 on M cells of murine ileal Peyer's patches in ligated ileal loops: an ultrastructural study. Microbiol Immunol 1986; 30:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/29\">",
"      Hughes EA, Gal&aacute;n JE. Immune response to Salmonella: location, location, location? Immunity 2002; 16:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/30\">",
"      Pace J, Hayman MJ, Gal&aacute;n JE. Signal transduction and invasion of epithelial cells by S. typhimurium. Cell 1993; 72:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/31\">",
"      Finlay BB, Gumbiner B, Falkow S. Penetration of Salmonella through a polarized Madin-Darby canine kidney epithelial cell monolayer. J Cell Biol 1988; 107:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/32\">",
"      Halle S, Bumann D, Herbrand H, et al. Solitary intestinal lymphoid tissue provides a productive port of entry for Salmonella enterica serovar Typhimurium. Infect Immun 2007; 75:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/33\">",
"      Steele-Mortimer O. The Salmonella-containing vacuole: moving with the times. Curr Opin Microbiol 2008; 11:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/34\">",
"      Kingsley RA, Humphries AD, Weening EH, et al. Molecular and phenotypic analysis of the CS54 island of Salmonella enterica serotype typhimurium: identification of intestinal colonization and persistence determinants. Infect Immun 2003; 71:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/35\">",
"      Hueck CJ, Hantman MJ, Bajaj V, et al. Salmonella typhimurium secreted invasion determinants are homologous to Shigella Ipa proteins. Mol Microbiol 1995; 18:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/36\">",
"      Gal&aacute;n JE. Molecular genetic bases of Salmonella entry into host cells. Mol Microbiol 1996; 20:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/37\">",
"      Lee CA, Jones BD, Falkow S. Identification of a Salmonella typhimurium invasion locus by selection for hyperinvasive mutants. Proc Natl Acad Sci U S A 1992; 89:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/38\">",
"      Behlau I, Miller SI. A PhoP-repressed gene promotes Salmonella typhimurium invasion of epithelial cells. J Bacteriol 1993; 175:4475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/39\">",
"      Ochman H, Soncini FC, Solomon F, Groisman EA. Identification of a pathogenicity island required for Salmonella survival in host cells. Proc Natl Acad Sci U S A 1996; 93:7800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/40\">",
"      Shea JE, Hensel M, Gleeson C, Holden DW. Identification of a virulence locus encoding a second type III secretion system in Salmonella typhimurium. Proc Natl Acad Sci U S A 1996; 93:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/41\">",
"      Hensel M, Shea JE, Waterman SR, et al. Genes encoding putative effector proteins of the type III secretion system of Salmonella pathogenicity island 2 are required for bacterial virulence and proliferation in macrophages. Mol Microbiol 1998; 30:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/42\">",
"      Watson PR, Paulin SM, Bland AP, et al. Characterization of intestinal invasion by Salmonella typhimurium and Salmonella dublin and effect of a mutation in the invH gene. Infect Immun 1995; 63:2743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/43\">",
"      Galyov EE, Wood MW, Rosqvist R, et al. A secreted effector protein of Salmonella dublin is translocated into eukaryotic cells and mediates inflammation and fluid secretion in infected ileal mucosa. Mol Microbiol 1997; 25:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/44\">",
"      Francis CL, Ryan TA, Jones BD, et al. Ruffles induced by Salmonella and other stimuli direct macropinocytosis of bacteria. Nature 1993; 364:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/45\">",
"      Ginocchio CC, Rahn K, Clarke RC, Gal&aacute;n JE. Naturally occurring deletions in the centisome 63 pathogenicity island of environmental isolates of Salmonella spp. Infect Immun 1997; 65:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/46\">",
"      McCormick BA, Colgan SP, Delp-Archer C, et al. Salmonella typhimurium attachment to human intestinal epithelial monolayers: transcellular signalling to subepithelial neutrophils. J Cell Biol 1993; 123:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/47\">",
"      T&uuml;kel C, Raffatellu M, Chessa D, et al. Neutrophil influx during non-typhoidal salmonellosis: who is in the driver's seat? FEMS Immunol Med Microbiol 2006; 46:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/48\">",
"      McCormick BA, Miller SI, Carnes D, Madara JL. Transepithelial signaling to neutrophils by salmonellae: a novel virulence mechanism for gastroenteritis. Infect Immun 1995; 63:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/49\">",
"      Jung HC, Eckmann L, Yang SK, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 1995; 95:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/50\">",
"      Miao EA, Alpuche-Aranda CM, Dors M, et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 2006; 7:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/51\">",
"      Sansonetti PJ, Phalipon A, Arondel J, et al. Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity 2000; 12:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/52\">",
"      Tsuji NM, Tsutsui H, Seki E, et al. Roles of caspase-1 in Listeria infection in mice. Int Immunol 2004; 16:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/53\">",
"      Mariathasan S, Weiss DS, Dixit VM, Monack DM. Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J Exp Med 2005; 202:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/54\">",
"      Lara-Tejero M, Sutterwala FS, Ogura Y, et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J Exp Med 2006; 203:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/55\">",
"      Finlay BB, Falkow S. Virulence factors associated with Salmonella species. Microbiol Sci 1988; 5:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/56\">",
"      Rahman MM, Guard-Petter J, Carlson RW. A virulent isolate of Salmonella enteritidis produces a Salmonella typhi-like lipopolysaccharide. J Bacteriol 1997; 179:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/57\">",
"      Kawasaki K, Ernst RK, Miller SI. 3-O-deacylation of lipid A by PagL, a PhoP/PhoQ-regulated deacylase of Salmonella typhimurium, modulates signaling through Toll-like receptor 4. J Biol Chem 2004; 279:20044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/58\">",
"      Khan SA, Everest P, Servos S, et al. A lethal role for lipid A in Salmonella infections. Mol Microbiol 1998; 29:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/59\">",
"      Guo L, Lim KB, Gunn JS, et al. Regulation of lipid A modifications by Salmonella typhimurium virulence genes phoP-phoQ. Science 1997; 276:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/60\">",
"      Bader MW, Sanowar S, Daley ME, et al. Recognition of antimicrobial peptides by a bacterial sensor kinase. Cell 2005; 122:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/61\">",
"      Nishino K, Latifi T, Groisman EA. Virulence and drug resistance roles of multidrug efflux systems of Salmonella enterica serovar Typhimurium. Mol Microbiol 2006; 59:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/62\">",
"      Aguero J, Faundez G, Nunez M, et al. Choleriform syndrome and production of labile enterotoxin (CT/LT1)-like antigen by species of Salmonella infantis and Salmonella haardt isolated from the same patient. Rev Infect Dis 1991; 13:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/63\">",
"      Chopra AK, Houston CW, Peterson JW, et al. Cloning and expression of the Salmonella enterotoxin gene. J Bacteriol 1987; 169:5095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/64\">",
"      Chopra AK, Huang JH, Xu X, et al. Role of Salmonella enterotoxin in overall virulence of the organism. Microb Pathog 1999; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/65\">",
"      Rahman H, Tschape H. Induction of Salmonella enterotoxin (stn) gene expression by epithelial cells (IEC-6). Indian J Exp Biol 1999; 37:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/66\">",
"      Garc&iacute;a-del Portillo F. Salmonella intracellular proliferation: where, when and how? Microbes Infect 2001; 3:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/67\">",
"      Alpuche-Aranda CM, Racoosin EL, Swanson JA, Miller SI. Salmonella stimulate macrophage macropinocytosis and persist within spacious phagosomes. J Exp Med 1994; 179:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/68\">",
"      Miller SI, Kukral AM, Mekalanos JJ. A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc Natl Acad Sci U S A 1989; 86:5054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/69\">",
"      Groisman EA, Chiao E, Lipps CJ, Heffron F. Salmonella typhimurium phoP virulence gene is a transcriptional regulator. Proc Natl Acad Sci U S A 1989; 86:7077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/70\">",
"      Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000; 68:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/71\">",
"      Fields PI, Swanson RV, Haidaris CG, Heffron F. Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc Natl Acad Sci U S A 1986; 83:5189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/72\">",
"      Guiney DG, Fang FC, Krause M, et al. Biology and clinical significance of virulence plasmids in Salmonella serovars. Clin Infect Dis 1995; 21 Suppl 2:S146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/73\">",
"      Libby SJ, Adams LG, Ficht TA, et al. The spv genes on the Salmonella dublin virulence plasmid are required for severe enteritis and systemic infection in the natural host. Infect Immun 1997; 65:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/74\">",
"      Ahmer BM, Tran M, Heffron F. The virulence plasmid of Salmonella typhimurium is self-transmissible. J Bacteriol 1999; 181:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/75\">",
"      Chiu CH, Chu C, Ou JT. Lack of evidence of an association between the carriage of virulence plasmid and the bacteremia of Salmonella typhimurium in humans. Microbiol Immunol 2000; 44:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/76\">",
"      Chang CC, Ou JT. Excess production of interleukin-12 subunit p40 stimulated by the virulence plasmid of Salmonella enterica serovar Typhimurium in the early phase of infection in the mouse. Microb Pathog 2002; 32:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/77\">",
"      Conlan JW. Neutrophils prevent extracellular colonization of the liver microvasculature by Salmonella typhimurium. Infect Immun 1996; 64:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/78\">",
"      Anand AJ, Glatt AE. Salmonella osteomyelitis and arthritis in sickle cell disease. Semin Arthritis Rheum 1994; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/79\">",
"      Mabey DC, Brown A, Greenwood BM. Plasmodium falciparum malaria and Salmonella infections in Gambian children. J Infect Dis 1987; 155:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/80\">",
"      Gopinath R, Keystone JS, Kain KC. Concurrent falciparum malaria and Salmonella bacteremia in travelers: report of two cases. Clin Infect Dis 1995; 20:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/81\">",
"      Gendrel D, Kombila M, Beaudoin-Leblevec G, Richard-Lenoble D. Nontyphoidal salmonellal septicemia in Gabonese children infected with Schistosoma intercalatum. Clin Infect Dis 1994; 18:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/82\">",
"      Wheat LJ, Rubin RH, Harris NL, et al. Systemic salmonellosis in patients with disseminated histoplasmosis. Case for 'macrophage blockade' caused by Histoplasma capsulatum. Arch Intern Med 1987; 147:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/83\">",
"      Miao EA, Andersen-Nissen E, Warren SE, Aderem A. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol 2007; 29:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/84\">",
"      Ramos JM, Garc&iacute;a-Corbeira P, Aguado JM, et al. Clinical significance of primary vs. secondary bacteremia due to nontyphoid Salmonella in patients without AIDS. Clin Infect Dis 1994; 19:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/85\">",
"      Gruenewald R, Blum S, Chan J. Relationship between human immunodeficiency virus infection and salmonellosis in 20- to 59-year-old residents of New York City. Clin Infect Dis 1994; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/86\">",
"      Levine WC, Buehler JW, Bean NH, Tauxe RV. Epidemiology of nontyphoidal Salmonella bacteremia during the human immunodeficiency virus epidemic. J Infect Dis 1991; 164:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/87\">",
"      Thamlikitkul V, Dhiraputra C, Paisarnsinsup T, Chareandee C. Non-typhoidal Salmonella bacteraemia: clinical features and risk factors. Trop Med Int Health 1996; 1:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/88\">",
"      Wolfe MS, Louria DB, Armstrong D, Blevins A. Salmonellosis in patients with neoplastic disease. A review of 100 episodes at Memorial Cancer Center over a 13-year period. Arch Intern Med 1971; 128:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/89\">",
"      Tumbarello M, Tacconelli E, Caponera S, et al. The impact of bacteraemia on HIV infection. Nine years experience in a large Italian university hospital. J Infect 1995; 31:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/90\">",
"      Mastroeni P, Simmons C, Fowler R, et al. Igh-6(-/-) (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent Salmonella enterica serovar typhimurium and show impaired Th1 T-cell responses to Salmonella antigens. Infect Immun 2000; 68:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/91\">",
"      Forrest BD. Impairment of immunogenicity of Salmonella typhi Ty21a due to preexisting cross-reacting intestinal antibodies. J Infect Dis 1992; 166:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19033/abstract/92\">",
"      MacLennan CA, Gilchrist JJ, Gordon MA, et al. Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science 2010; 328:508.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2700 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19033=[""].join("\n");
var outline_f18_37_19033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4395261\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Serotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sources of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infectious dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interaction of Salmonellae with enteric host defenses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mechanisms of adherence and invasion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathogenicity islands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inflammatory response mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Survival within phagocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Role of virulence plasmids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immune response to Salmonella infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Innate immune system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cell-mediated immunity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Humoral immune responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4395261\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2700\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2700|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/7/36984\" title=\"figure 1\">",
"      Salmonellosis risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/23/24959\" title=\"figure 2\">",
"      Salmonella secretion system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2700|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/6/4204\" title=\"table 1\">",
"      Salmonella serogroups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/18/24875\" title=\"table 2\">",
"      Host factors Salmonella",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=related_link\">",
"      Approach to the patient with nontyphoidal Salmonella in a stool culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24265?source=related_link\">",
"      Differential diagnosis of microbial foodborne disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42008?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=related_link\">",
"      Pathogenesis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/31/27122?source=related_link\">",
"      Patient information: Salmonellosis (Salmonella) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=related_link\">",
"      Zoonoses from cats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=related_link\">",
"      Zoonoses from dogs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=related_link\">",
"      Zoonoses from pets other than dogs and cats",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_37_19034="Overview of homocysteine";
var content_f18_37_19034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of homocysteine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/37/19034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19034/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19034/contributors\">",
"     David S Kang, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/37/19034/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19034/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19034/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/37/19034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/37/19034/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/37/19034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homocysteine is an intermediary amino acid formed by the conversion of methionine to cysteine. Homocystinuria or severe hyperhomocysteinemia is a rare autosomal recessive disorder characterized by severe elevations in plasma and urine homocysteine concentrations. Clinical manifestations of homocystinuria include developmental delay, osteoporosis, ocular abnormalities, thromboembolic disease, and severe premature atherosclerosis. Homocystinuria is not discussed further in this topic review.",
"   </p>",
"   <p>",
"    Less marked elevations in plasma homocysteine are much more common, occurring in 5 to 7 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although unassociated with the clinical stigmata of homocystinuria, mounting evidence suggests that moderate hyperhomocysteinemia is an independent risk factor for atherosclerotic vascular disease and for recurrent venous thromboembolism.",
"   </p>",
"   <p>",
"    This topic will review the risks associated with elevated homocysteine levels, screening for hyperhomocysteinemia, and the evidence evaluating the use of vitamin supplements that lower homocysteine levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF HYPERHOMOCYSTEINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homocysteine is metabolized by one of two divergent pathways: transsulfuration and remethylation (",
"    <a class=\"graphic graphic_figure graphicRef72986 \" href=\"UTD.htm?7/40/7814\">",
"     figure 1",
"    </a>",
"    ). The transsulfuration of homocysteine to cysteine is catalyzed by cystathionine-&szlig;-synthase, a process that requires pyridoxal phosphate (vitamin B6) as a cofactor. Remethylation of homocysteine produces methionine. This reaction is catalyzed either by methionine synthase or by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41747?source=see_link\">",
"     betaine",
"    </a>",
"    -homocysteine methyltransferase. Vitamin B12 (cobalamin) is the precursor of methylcobalamin, which is the cofactor for methionine synthase.",
"   </p>",
"   <p>",
"    Elevations in the plasma homocysteine concentration can occur due to genetic defects in the enzymes involved in homocysteine metabolism, to nutritional deficiencies in vitamin cofactors, or to other factors including some chronic medical conditions and drugs (",
"    <a class=\"graphic graphic_figure graphicRef72986 \" href=\"UTD.htm?7/40/7814\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. Some drugs used in the treatment of hypercholesterolemia, such as fibrates and nicotinic acid, can raise homocysteine levels by approximately 30 percent; however, the clinical significance of this is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Cigarette smoking also may elevate homocysteine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/13\">",
"     13",
"    </a>",
"    ]. Chronic kidney failure can increase homocysteine levels due to decreased renal removal and impaired metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link&amp;anchor=H18#H18\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\", section on 'Hyperhomocysteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Thermolabile variant of MTHFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common form of genetic hyperhomocysteinemia results from production of a thermolabile variant of methylene tetrahydrofolate reductase (MTHFR) with reduced enzymatic activity (T mutation) (",
"    <a class=\"graphic graphic_figure graphicRef72986 \" href=\"UTD.htm?7/40/7814\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/14\">",
"     14",
"    </a>",
"    ]. The gene encoding for this variant contains a cytosine to thymine substitution at nucleotide 677 (C677T) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The responsible gene is common, with a population frequency estimated between 5 to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Homozygosity for the thermolabile variant of MTHFR (TT genotype) is a relatively common cause of mildly elevated plasma homocysteine levels in the general population, often occurring in association with low serum folate levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. As an example, one study of 625 men found that 11.5 percent were homozygous for the TT genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/18\">",
"     18",
"    </a>",
"    ]. However, for those in the top 5 and 10 percent of plasma homocysteine concentrations, the frequency rose to 48 and 36 percent, respectively. Homozygotes also had the lowest serum folate concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vitamin deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased blood levels of homocysteine may reflect deficiency of folate, vitamin B6,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin B12&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Plasma folate and B12 levels, in particular, are strong determinants of the homocysteine concentration. Homocysteine levels are inversely related to folate consumption, reaching a stable baseline level when folate intake exceeds 400",
"    <span class=\"nowrap\">",
"     &micro;g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Vitamin B6 is a weaker determinant [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of vitamin deficiency in the pathogenesis of hyperhomocysteinemia was evaluated in a cohort of 1041 elderly subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/24\">",
"     24",
"    </a>",
"    ]. Two-thirds of patients with elevated homocysteine levels had a subnormal plasma concentration of folate, vitamin B12, or pyridoxal-5-phosphate (the coenzyme form of vitamin B6). The prevalence of low plasma B12 levels was higher in this cohort than in the younger participants in a European case-control study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/25\">",
"     25",
"    </a>",
"    ]. These data suggest that suboptimal B12 intake coupled with poorer absorption might play a greater role in elevating homocysteine and subsequent CHD risk in older adults than in younger patients. In contrast, folate intake low enough to raise plasma homocysteine may be relatively common in the general population, particularly in moderate consumers of alcohol.",
"   </p>",
"   <p>",
"    Further evidence of the importance of vitamin deficiency comes from a report that assessed the results of the United States Food and Drug Administration regulation requiring all enriched grain products be fortified with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . Patients who had blood tested following fortification had significantly higher blood folate concentrations and lower homocysteine concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, the prevalence of a high homocysteine concentration (&gt;13",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    decreased from 18.7 before fortification to 9.8 percent after fortification.",
"   </p>",
"   <p>",
"    Additional support for the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    and perhaps vitamin B6 in hyperhomocysteinemia comes from a trial that randomly assigned 158 healthy siblings of 167 patients with premature atherothrombotic disease to folic acid (5 mg daily) and vitamin B6 (250 mg daily) or placebo; most of the siblings and all of the patients had postmethionine loading hyperhomocysteinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/23\">",
"     23",
"    </a>",
"    ]. After a two-year follow-up, fasting and postmethionine homocysteine levels significantly decreased with vitamin supplementation, from 14.7 to 7.4",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    and 64.9 to 34.9",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    respectively, while there were no changes with placebo therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ATHEROTHROMBOTIC PROPERTIES OF HOMOCYSTEINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homocysteine has primary atherogenic and prothrombotic properties. Histopathologic hallmarks of homocysteine-induced vascular injury include intimal thickening, elastic lamina disruption, smooth muscle hypertrophy, marked platelet accumulation, and the formation of platelet-enriched occlusive thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. These observations may help explain the association between hyperhomocysteinemia and cardiovascular disease described below.",
"   </p>",
"   <p>",
"    There are multiple mechanisms by which homocysteine may induce vascular injury:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Homocysteine promotes leukocyte recruitment by upregulating monocyte chemoattractant protein-1 and interleukin-8 expression and secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The thiolactone metabolite of homocysteine can combine with LDL-cholesterol to produce aggregates that are taken up by vascular macrophages in the arterial intima; these foam cells may then release the lipid into atherosclerotic plaques [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Homocysteine increases smooth muscle cell proliferation and enhances collagen production [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prothrombotic effects of homocysteine, which have been demonstrated in patients with acute coronary syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/34\">",
"       34",
"      </a>",
"      ], include attenuation of endothelial cell tissue plasminogen activator binding sites, activation of factor VIIa and V, inhibition of protein C and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      sulfate, increased fibrinopeptide A and prothrombin fragments 1 and 2, increased blood viscosity, and decreased endothelial antithrombotic activity due to changes in thrombomodulin function [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/35-40\">",
"       35-40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"       \"Overview of hemostasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oxidative stress by free radicals formed during the oxidation of reduced homocysteine may directly injure endothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/41,42\">",
"       41,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Marked platelet accumulation may be secondary to direct proaggregatory effects of homocysteine or to an impairment in endothelium-mediated platelet inhibition [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolonged exposure of endothelial cells to homocysteine reduces the activity of dimethylarginine dimethylaminohydrolase, the enzyme that degrades asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase; this impairs the production of nitric oxide [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/43,45\">",
"       43,45",
"      </a>",
"      ]. This may contribute to impaired endothelium-dependent vasodilation of both conduit and resistance vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"       \"Endothelial dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support for the role of homocysteine in endothelial dysfunction is derived from studies that found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation both lowers the homocysteine concentration and improves measures of endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternate view is that hyperhomocysteinemia is not directly harmful, but that it indirectly inhibits methyl fluxes during transmethylation of methionine; the resulting impairment of DNA methylation could then affect many physiologic processes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/52\">",
"     52",
"    </a>",
"    ]. A study in patients with uremia and hyperhomocysteinemia found increased levels of DNA hypomethylation and altered gene expression that were corrected by administration of folate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensitive assays allow quantification of the total plasma homocysteine concentration; approximately 75 to 85 percent is protein-bound and 15 to 25 percent is in acid-soluble free forms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/54\">",
"     54",
"    </a>",
"    ]. Normal homocysteine concentrations range between 5 and 15",
"    <span class=\"nowrap\">",
"     &micro;mol/L.",
"    </span>",
"    Hyperhomocysteinemia has been classified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate (15 to 30",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Intermediate (30 to 100",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Severe (&gt;100",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An oral methionine challenge (100",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be given to patients suspected of hyperhomocysteinemia who have normal fasting homocysteine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/56\">",
"     56",
"    </a>",
"    ]. The oral methionine challenge is more useful for patients with cystathione-beta-synthase deficiency than for those MTHFR reductase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/16\">",
"     16",
"    </a>",
"    ]. The homocysteine concentration is measured on fasting samples before the methionine challenge and four and eight hours afterward. The patient is classified as having impaired homocysteine metabolism if the four hour post-methionine plasma homocysteine concentration exceeds the appropriate mean level by more than two standard deviations (",
"    <a class=\"graphic graphic_table graphicRef79494 \" href=\"UTD.htm?21/55/22395\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, the prognostic significance of the oral methionine challenge is uncertain. In one series that included 24 of 163 subjects with homozygosity for the thermolabile variant, fasting but not postmethionine total homocysteine levels were associated with CHD status [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homocysteine levels measured at the time of admission for acute myocardial infarction and unstable angina appear to be accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/57\">",
"     57",
"    </a>",
"    ]. In this small study, levels at admission were similar to those six months after the acute event, but there were minor variations in the homocysteine level during the first week after admission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ROLE IN VASCULAR DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hyperhomocysteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early data on the relationship between elevated blood homocysteine concentrations and coronary heart disease (CHD) and stroke have been somewhat inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/58-63\">",
"     58-63",
"    </a>",
"    ], high homocysteine levels appear to be clearly associated with an increased risk of cardiovascular and cerebrovascular disease. However, homocysteine does not appear to be as important as other risk factors such as hypercholesterolemia, smoking, diabetes mellitus, and hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H1268156#H1268156\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Vitamins, antioxidants and homocysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis that evaluated data from 30 prospective and retrospective studies, involving 5073 ischemic heart disease and 1113 stroke events, provides an analysis of the varied data [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/64\">",
"     64",
"    </a>",
"    ]. Stronger associations between the blood homocysteine concentration and cardiovascular events were noted in retrospective compared with prospective studies. After adjustment for known cardiovascular risk factors, a 25 percent lower homocysteine concentration (about 3",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    in the prospective studies was associated with a lower risk of ischemic heart disease risk (odds ratio 0.89, 95% CI 0.83-0.86) and stroke (odds ratio 0.81, 95% CI 0.69-0.95).",
"   </p>",
"   <p>",
"    These results are supported by a meta-analysis of 40 observational studies involving 11,162 patients who were homozygous for the thermolabile variant of MTHFR and 12,758 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/65\">",
"     65",
"    </a>",
"    ]. Patients with the MTHFR TT genotype had a 16 percent higher odds of coronary heart disease compared with controls (odds ratio 1.16, 95% CI 1.05-1.28). Additionally, the MTHFR TT genotype is associated with an increased risk of silent brain infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis performed for the US Preventive Services Task Force specifically examined the issue of whether homocysteine levels add predictive value for determining the risk of CHD in adults without known CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/67\">",
"     67",
"    </a>",
"    ]. The analysis found that, independent of Framingham risk factors, each increase in homocysteine level of 5",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    increases the risk of CHD events by approximately 20 percent.",
"   </p>",
"   <p>",
"    Hyperhomocysteinemia has been linked to the following vascular events:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myocardial infarction, other acute coronary syndromes, and recurrent coronary events [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/34,68-74\">",
"       34,68-74",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Premature coronary heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/71,75,76\">",
"       71,75,76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cardiovascular and total mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/74,77-79\">",
"       74,77-79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Adverse outcomes after angioplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/80\">",
"       80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Carotid artery stenosis (",
"      <a class=\"graphic graphic_figure graphicRef78030 \" href=\"UTD.htm?21/48/22285\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/81-83\">",
"       81-83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/84-88\">",
"       84-88",
"      </a>",
"      ], recurrent stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/89\">",
"       89",
"      </a>",
"      ], and silent brain infarct [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/90\">",
"       90",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Homocysteine levels have also been linked to the development of heart failure. A community-based cohort study found that higher homocysteine levels increased the risk of heart failure even after controlling for interim myocardial infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of whether homocysteine plays a causal role in cardiovascular disease or whether there is a non-causal association has additionally been addressed by meta-analyses that have looked at both prospective studies and MTHFR mutation studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Similar odds ratios for cardiovascular disease were found in both types of studies. The consistent odds ratios across studies that should have had distinct sources of bias and error argue in favor of a causal role for homocysteine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/94\">",
"     94",
"    </a>",
"    ]. In contrast, a subsequent meta-analysis of MTHFR mutation studies found no evidence of a causal relationship between homocysteine and coronary heart disease in studies of North American, European, and Australian populations, but did find such evidence in studies of Middle Eastern and Asian populations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/95\">",
"     95",
"    </a>",
"    ]. The study found evidence of publication bias, and the authors felt the results could potentially be explained by such bias or by geographic variability in folate intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vitamin status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have also contributed to our knowledge regarding the complex relationship between the blood homocysteine concentration, vitamin status, and the risk of cardiovascular disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-control study that evaluated 750 patients with documented vascular disease and 800 control subjects, low levels of folate and vitamin B6 were associated with an increased risk for atherosclerosis, independent of conventional risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/20\">",
"       20",
"      </a>",
"      ]. The risk associated with folate was in part explained by increased serum homocysteine, while the relationship between vitamin B6 and atherosclerosis was independent of the homocysteine concentration.",
"     </li>",
"     <li>",
"      The Nurses' Health Study found a graded inverse association between higher dietary intakes of folate and vitamin B6 and CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/21\">",
"       21",
"      </a>",
"      ]. The lowest risk was seen in women in the highest quintile of intake for both folate and vitamin B6 (40 percent risk reduction). This lowest risk group had a dietary intake of folate above 545",
"      <span class=\"nowrap\">",
"       micrograms/day",
"      </span>",
"      and an average intake of vitamin B6 above 5.9",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      which are well above the current RDAs (400",
"      <span class=\"nowrap\">",
"       micrograms/day",
"      </span>",
"      and 1.6",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      respectively) (",
"      <a class=\"graphic graphic_figure graphicRef51335 \" href=\"UTD.htm?5/7/5247\">",
"       figure 3",
"      </a>",
"      ). The benefits of folate supplementation were greatest in women consuming the most alcohol, probably because alcohol increases folate metabolism and these women were relatively deficient to start. No association was observed between dietary vitamin B12 and CHD.",
"     </li>",
"     <li>",
"      The Health Professional Follow-up Study of 43,732 men ages 40 to 75 who were free of cardiovascular disease and diabetes at baseline found in a multivariate analysis that compared with men in the lowest quintile of folate intake, men in the highest quintile had a relative risk of ischemic stroke of 0.71 (95% CI 0.52-0.96) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/96\">",
"       96",
"      </a>",
"      ]. No significant association was found between hemorrhagic stroke and folate intake. Intake of vitamin B12, but not vitamin B6, was also inversely associated with the risk of ischemic stroke.",
"     </li>",
"     <li>",
"      An association between dietary folate and atherosclerosis was demonstrated in a prospective study of 1980 men, ages 42 to 60 years, who were followed for 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/22\">",
"       22",
"      </a>",
"      ]. Those in the highest quintile of folate intake (&gt;297",
"      <span class=\"nowrap\">",
"       &micro;g/day,",
"      </span>",
"      mean intake 342.1",
"      <span class=\"nowrap\">",
"       &micro;g/day)",
"      </span>",
"      had a relative risk of an acute coronary event of 0.45 compared to those in the lowest quintile (&lt;211",
"      <span class=\"nowrap\">",
"       &micro;g/day,",
"      </span>",
"      mean intake 187.7",
"      <span class=\"nowrap\">",
"       &micro;g/day);",
"      </span>",
"      there was no association with B6 intake and only a weak association with the B12 intake.",
"     </li>",
"     <li>",
"      In the meta-analysis of MTHFR mutations discussed above, there was significant heterogeneity between studies performed in European compared with North American populations, with a significant association between the TT genotype and coronary disease in the former but not the latter [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/65\">",
"       65",
"      </a>",
"      ]. This heterogeneity may be explained by differences in folate status; the North American studies were performed after 1995, at a time when there was greater use of B vitamin supplements and folate fortification. Thus, adequate folate status appears to minimize the effect that the MTHFR TT genotype has on risk of cardiovascular disease. Another possible explanation is the difference in vitamin B2 (riboflavin) fortification in North America and Europe. A randomized trial found that vitamin B2 supplementation lowered homocysteine levels in patients with the MTHFR TT genotype but not in those with other genotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low levels of vitamin B6 may be independently associated with CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/98\">",
"       98",
"      </a>",
"      ]. After adjusting for other risk factors, higher plasma concentrations of pyridoxal 5'-phosphate were associated with a lower incidence of CHD; the relative risk for the highest versus lowest quintile was 0.28. This is supported by the data from a multicenter European study that showed that vitamin B6 was directly related to CHD risk independent of homocysteine levels [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/25\">",
"       25",
"      </a>",
"      ]. Vitamin B6 may be more effective in counteracting the effects of methionine loading (simulating the fed state) on homocysteine levels, while folate may be more important in regulating plasma homocysteine in the fasting state [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/99,100\">",
"       99,100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data from studies are somewhat inconsistent, however. As an example, an Australian cohort study of 2950 people followed for 29 years that did not measure homocysteine concentration found no independent association of baseline serum folate, red cell folate, and serum vitamin B12 concentrations with mortality from cardiovascular disease after adjusting for age and other standard risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ROLE IN VENOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that hyperhomocysteinemia is a risk factor for venous thromboembolic disease (pulmonary embolism and deep vein thrombosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Meta-analyses of case-control studies have found an odds ratio of 2.5 to 2.95 for venous thromboembolic disease in patients with homocysteine levels more than two standard deviations above the mean value of control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/103,104\">",
"     103,104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Moderate hyperhomocysteinemia (15 to 30",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    may also be a risk factor for recurrent venous thrombosis. This was illustrated in a multicenter study in which patients with a single episode of idiopathic venous thromboembolism were prospectively followed after discontinuation of oral anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/105\">",
"     105",
"    </a>",
"    ]. Recurrent venous thromboembolism was significantly more likely in the 66 patients with hyperhomocysteinemia than in the 198 with normal levels (18.2 percent versus 8.1 percent, respectively).",
"   </p>",
"   <p>",
"    Some studies have suggested that the risk of thrombosis increases 10 to 50-fold in patients who have both homocysteinemia and an inherited thrombophilia (eg, factor V Leiden) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. However, other studies have failed to confirm these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/108\">",
"     108",
"    </a>",
"    ]. These contradictory results may reflect statistical anomalies due to the small number of patients that have both defects. Further confusing the issue, most studies that have examined patients with the thermolabile variant of MTHFR have not found that this genotype increases the risk of venous thrombosis when found alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/109-111\">",
"     109-111",
"    </a>",
"    ], or when associated with factor V Leiden or the prothrombin mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/108,110\">",
"     108,110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Obstetric complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thermolabile variant of MTHFR has been linked to obstetric complications such as severe preeclampsia, abruptio placentae, fetal growth restriction, and stillbirth, which are associated with intervillous or spiral artery thrombosis and inadequate placental perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/112\">",
"     112",
"    </a>",
"    ]. Women with an obstetric complication were significantly more likely to have the thermolabile variant of MTHFR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ROLE IN OTHER CONDITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Birth defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplementation with folate reduces the risk of neural tube defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link&amp;anchor=H3#H3\">",
"     \"Vitamin supplementation in disease prevention\", section on 'Folic acid'",
"    </a>",
"    .) Homozygosity and heterozygosity for the thermolabile variant of MTHFR appear to be associated with an increased risk of neural tube defects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homocystinuria is associated with the early onset of osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10073?source=see_link\">",
"     \"The child with tall stature or abnormally rapid growth\"",
"    </a>",
"    .) High homocysteine levels in adults have been associated with osteoporotic fractures in some [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/114-117\">",
"     114-117",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/118\">",
"     118",
"    </a>",
"    ], studies.",
"   </p>",
"   <p>",
"    Supplementation with folate and vitamin B12 in high risk groups may reduce the risk of fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Folate/vitamin B12'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not clear, however, whether high levels of homocysteine have a direct effect on bone or whether the effect is mediated through another factor, such as poor nutrition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is conflicting evidence about whether homocysteine is an independent risk factor for dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=see_link&amp;anchor=H417059#H417059\">",
"     \"Risk factors for dementia\", section on 'Homocysteine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SCREENING FOR HYPERHOMOCYSTEINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bulk of data suggest that hyperhomocysteinemia is an independent risk factor for cerebrovascular, peripheral vascular, and coronary heart disease, and for venous thromboembolic disease. However, this relationship alone does not provide a compelling argument for population screening [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/120\">",
"     120",
"    </a>",
"    ]. The arguments against screening in the general population include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identifying patients with the TT genotype of MTHFR is unlikely to be cost-effective. Combining the prevalence of the TT genotype (approximately 11 percent) and the relative risk, it is possible to estimate the population attributable risk (the proportion of coronary heart disease that would be eliminated from the population if the genetic variant did not exist) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/121\">",
"       121",
"      </a>",
"      ]. For the TT genotype, the population attributable risk is only 1 to 2 percent. In addition, adequate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      intake further reduces the impact of the genetic variant.",
"     </li>",
"     <li>",
"      While screening for hyperhomocysteinemia itself is not difficult, a benefit from lowering the homocysteine concentration on cardiovascular and venous thromboembolic disease remains unproven (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/103,122\">",
"       103,122",
"      </a>",
"      ]. Thus, even if we identify patients with an elevated homocysteine concentration it is not clear that acting on this information is of benefit.",
"     </li>",
"     <li>",
"      Even if treatment of hyperhomocysteinemia is beneficial, it may be more cost effective to recommend that people take a daily multivitamin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"       \"Vitamin supplementation in disease prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additionally, measurement variability of homocysteine is a significant problem in determining appropriate candidates for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized clinical trials are underway to address the effect of folate, B6, and B12 supplementation in primary prevention of cardiovascular disease.",
"   </p>",
"   <p>",
"    Until the results of these studies are available, and given the negative results of using supplementation for secondary prevention, we recommend not screening for hyperhomocysteinemia. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Secondary prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no high quality evidence from trials with clinical endpoints to support treating patients who do not have severe hyperhomocysteinemia (homocystinuria).",
"   </p>",
"   <p>",
"    The majority of hyperhomocysteinemia is caused by low levels of folate and vitamin B12 in patients with or without the thermolabile variant of MTHFR [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/124\">",
"     124",
"    </a>",
"    ]. Correcting nutritional inadequacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , vitamin B12, and choline (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41747?source=see_link\">",
"     betaine",
"    </a>",
"    ) will lower homocysteine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/124\">",
"     124",
"    </a>",
"    ]. A diet rich in fruits, vegetables, and low-fat dairy products and low in saturated and total fat also can lower fasting serum homocysteine [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients who are treated beyond diet, the treatment varies with the underlying cause, but generally involves vitamin supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , vitamin B12, and vitamin B6.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lowering homocysteine levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin supplementation with folate lowers homocysteine levels. In patients who are treated to lower homocysteine levels, we suggest treating with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    vitamin B6 (10",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and vitamin B12 (0.4",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    All patients should receive a B complex vitamin to mitigate against peripheral neuropathy. Normalization of the homocysteine concentration has been reported within two weeks, but further lowering of homocysteine levels occurs by six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/126\">",
"     126",
"    </a>",
"    ]. The dose of folic acid should be increased up to 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as needed to lower the homocysteine concentration below 15",
"    <span class=\"nowrap\">",
"     &micro;mol/L.",
"    </span>",
"    In patients with a homocysteine concentration &gt;30",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    or chronic renal failure the initial dose of folic acid is 5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    The",
"    effect of dose and treatment duration was illustrated in a study in which 37 otherwise normal subjects with persistent hyperhomocysteinemia were treated with 0.2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/17\">",
"     17",
"    </a>",
"    ]. The plasma homocysteine concentration was reduced in almost all within seven weeks and fell to the normal range in 21 by seven months; most of the remaining subjects attained normal homocysteine concentrations on a higher folate dose of 5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Supplementation with folate has shown the following dose-response relationships in patients with CHD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 75 patients, cereal providing 127 &micro;g of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      daily increased plasma folic acid by 31 percent and reduced homocysteine by 3.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/127\">",
"       127",
"      </a>",
"      ]. Cereals providing 499 and 665 &micro;g of folic acid per day raised plasma folic acid by 65 and 106 percent, respectively and lowered plasma homocysteine by 11 and 14 percent, respectively.",
"     </li>",
"     <li>",
"      In the PACIFIC trial, 723 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      (2.0 or 0.2",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/128\">",
"       128",
"      </a>",
"      ]. The fall in serum homocysteine was significantly greater at the higher dose (16 versus 11 percent, 1.8 versus 1.2",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the data are limited, in refractory cases we begin therapy with trimethylglycine (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41747?source=see_link\">",
"     betaine",
"    </a>",
"    ) 750 mg twice daily and increase the dose as necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of randomized clinical trials for supplementation aimed at lowering homocysteine levels in patients with established cardiovascular disease demonstrated somewhat controversial results",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/129-133\">",
"     129-133",
"    </a>",
"    ]. However, most studies have generally found no decrease in cardiovascular events or death.",
"   </p>",
"   <p>",
"    In one of the largest trials included in these meta-analyses, the HOPE-2 trial, 5522 patients ages 55 and older with known vascular disease or diabetes were randomly assigned to receive supplementation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    2.5 mg daily, vitamin B6 50 mg daily, and vitamin B12 1 mg daily, or to receive placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/134\">",
"     134",
"    </a>",
"    ]. Mean homocysteine levels decreased by 2.4",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    in patients in the supplement group and increased by 0.8",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    in the placebo group. After a mean follow-up of five years, treatment with supplementation had no effect on the primary combined endpoint of cardiovascular death, myocardial infarction, and stroke (relative risk 0.95, 95% CI 0.84-1.07). There was also no benefit in patients with higher baseline homocysteine levels.",
"   </p>",
"   <p>",
"    Although these results make it unlikely that reducing homocysteine levels with B-vitamin supplement is beneficial for the prevention of cardiovascular disease, it remains possible that design of the trials could have led to a benefit being missed. Most trials did not assess for overt homocysteinemia and adequate nutritional conditions, particularly folate and other B-vitamins. This limits the power of trials to detect benefits, particularly in populations that consume foods fortified with folate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/54\">",
"     54",
"    </a>",
"    ]. The above trials were performed in regions with a high folate concentration in the population and also included many patients without elevated homocysteine levels. In addition, control subjects received daily vitamin mixtures containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . It is noteworthy to find marked effects on homocysteine concentration due to the thermolabile MTHFR as well as in the probability for stroke in a population low in folate consumption, such as Asian countries, compared with areas in the folate fortification [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/135\">",
"     135",
"    </a>",
"    ]. Trials performed in the future that target a specific homocysteine level in patients with baseline hyperhomocysteinemia, or that dose supplements to achieve specific serum folate or vitamin B12 levels, might be able to demonstrate clinical benefit.",
"   </p>",
"   <p>",
"    In summary, the current trials found no benefits, even in the subsets of patients with elevated homocysteine levels at baseline. In the absence of demonstrable benefit and the absence of trials looking at subsets of patients with much more elevated homocysteine levels, we recommend not treating hyperhomocysteinemia for secondary prevention in patients with cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     After PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the specific case of supplementation after percutaneous coronary intervention (PCI), there is conflicting evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of a daily combination supplement (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      1 mg, vitamin B12 400 mcg, vitamin B6 10 mg) in 553 patients undergoing PCI found a decreased incidence of major adverse events after an average follow-up of 11 months [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/136\">",
"       136",
"      </a>",
"      ]. The risk for a composite end point (death, nonfatal myocardial infarction, need for repeat revascularization) was significantly lower in patients receiving the supplement than in those receiving a placebo (15.4 percent versus 22.8 percent) primarily due to a reduced rate of target lesion revascularization (9.9 percent versus 16.0 percent). There was a trend toward fewer deaths (1.5 versus 2.8 percent, relative risk 0.54 [95% CI 0.16-1.70]) and toward fewer nonfatal myocardial infarctions (2.6 versus 4.3 percent, relative risk 0.60 [CI 0.24 to 1.51]). Only 29 percent of the patients had baseline elevated homocysteine levels (above 12",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      and none had severe hyperhomocysteinemia (above 100",
"      <span class=\"nowrap\">",
"       &micro;mol/L).",
"      </span>",
"     </li>",
"     <li>",
"      In contrast, a randomized trial of supplementation after coronary stent placement found that patients in the treatment group had higher rates of restenosis (34.5 versus 26.5 percent) and a higher percentage required target-vessel revascularization (15.8 versus 10.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/137\">",
"       137",
"      </a>",
"      ]. Supplementation consisted of an initial intravenous bolus injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      1 mg, vitamin B12 1 mg, and vitamin B6 5 mg, followed by daily oral administration of folic acid 1.2 mg, vitamin B12 60 mcg, and vitamin B6 48 mg. In subset analyses, there was a trend toward lower rates of restenosis in women, patients with diabetes, and patients with homocysteine levels of 15",
"      <span class=\"nowrap\">",
"       &micro;mol/L",
"      </span>",
"      or more. The applicability of these results to patients who have received drug-eluting stents, which greatly reduce rates of stent restenosis, is unknown.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The explanation for these conflicting results in PCI is uncertain; however, in the first study only about half the patients received stents. The authors of the second study suggest that supplementation may promote smooth muscle proliferation and matrix formation, which are important parts of restenosis after stenting. Lowering of homocysteine may play a protective role on the thrombus formation within intimal cracks and vascular remodeling that are important after balloon angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/137\">",
"     137",
"    </a>",
"    ]. Additionally, the second study used different doses of vitamins and gave an initial intravenous bolus, and in particular used much higher doses of vitamin B6. These higher doses of vitamin B6 could influence the metabolism of homocysteine with a potentially greater effect on the vitamin B6-dependent transsulfuration pathway than on the vitamin B12-dependent and folate-dependent remethylation pathways (",
"    <a class=\"graphic graphic_figure graphicRef72986 \" href=\"UTD.htm?7/40/7814\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The various trials discussed above used differing doses of folate, vitamin B6, vitamin B12. One possible interpretation of the results is that high level supplementation with vitamin B6",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitamin B12 is harmful while high dose folate supplementation might be beneficial. However, given the generally negative results in secondary prevention, the one trial showing a benefit may have found these results by random chance.",
"   </p>",
"   <p>",
"    At this point, there is inadequate evidence for benefit. We do not recommend the use of vitamin supplements to lower homocysteine levels in patients with CHD including in patients who have recently undergone PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, hyperhomocysteinemia is a risk factor for venous thromboembolic disease (VTE, pulmonary embolism and deep vein thrombosis). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Role in venous thromboembolism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, randomized trials have not found benefits on rates of VTE with vitamin therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial examined the role of homocysteine lowering with daily B vitamins (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      5 mg, vitamin B6 50 mg, vitamin B12 0.4 mg) in 701 patients with a first episode of VTE [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/139\">",
"       139",
"      </a>",
"      ]. There was no statistically significant reduction in recurrent VTE in patients treated with B vitamins (hazard ratio [HR] 0.84, 95% CI 0.56-1.26). There was also no reduction in recurrent VTE in the 360 patients with baseline homocysteine levels above the 75th percentile (HR 1.14, CI 0.65-1.98), or in the 341 patients with normal homocysteine levels (HR 0.58, CI 0.31-1.07).",
"     </li>",
"     <li>",
"      A secondary analysis from the HOPE-2 trial, described above (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Cardiovascular disease'",
"      </a>",
"      above), found no effect of vitamin therapy on rates of VTE (HR 1.01, CI 0.66-1.53) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/140\">",
"       140",
"      </a>",
"      ]. Vitamin therapy also did not appear to be effective in the 821 patients with a baseline homocysteine in the highest quartile in the study (&gt;13.8",
"      <span class=\"nowrap\">",
"       &micro;mol/L),",
"      </span>",
"      however, the confidence intervals were wide (HR 1.71, CI 0.48-6.06).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on these data, we suggest not screening for or treating hyperhomocysteinemia in patients with VTE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUPPLEMENTATION IN THE GENERAL POPULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large randomized clinical trials of vitamin B6, vitamin B12, and folate for the primary prevention of cardiovascular disease and stroke are underway [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/141\">",
"     141",
"    </a>",
"    ]. These studies include large numbers of subjects and various doses and combinations of vitamins and will likely guide future recommendations for supplementation.",
"   </p>",
"   <p>",
"    Until the results of these trials are available, decisions about the utility of supplementation in the general population must be based on extrapolation from observational data showing associations between homocysteine levels, vitamin levels, and vascular disease (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Vitamin status'",
"    </a>",
"    above); from data from interventional trials showing the effects of supplementation on homocysteine levels; and from secondary prevention trials. It is uncertain whether relatively short-term trials of supplements in secondary prevention apply to long-term treatment for primary prevention, but with several other forms of therapy (eg, statins, hormone replacement) effects in primary prevention appear similar to those first demonstrated in secondary prevention.",
"   </p>",
"   <p>",
"    A meta-analysis assessed the effects of supplementation in 12 trials with 1114 people [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/142\">",
"     142",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    in a dose of 0.5 to 5.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    lowered serum homocysteine by 25 percent (95% CI 23-38 percent); vitamin B12 at 0.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    provided an additional reduction of 7 percent (95% CI 3-10 percent), while vitamin B6 had no additional effect (however, this study did not consider homocysteine levels after methionine loading). A similar effect of folic acid has been noted in subsequent clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/127,128,143\">",
"     127,128,143",
"    </a>",
"    ]. The effect would be expected to be less in patients with lower baseline serum homocysteine and higher baseline serum folate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/128\">",
"     128",
"    </a>",
"    ]. One report found that a folic acid dose of 0.8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was necessary to achieve the maximum reduction in serum homocysteine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/37/19034/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of stronger evidence, and given the lack of benefit in secondary prevention trials, we do not recommend vitamin supplementation for the purpose of lowering homocysteine levels for primary prevention of cardiovascular disease. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Secondary prevention'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperhomocysteinemia appears to be an independent risk factor for cerebrovascular, peripheral arterial, and coronary heart disease, and for venous thromboembolic disease. However, it does not appear to be as important as other cardiovascular risk factors such as hypercholesterolemia, smoking, diabetes mellitus, and hypertension.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest not screening for hyperhomocysteinemia, including in patients with otherwise unexplained venous thrombosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Screening for hyperhomocysteinemia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Venous thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with cardiovascular disease NOT be treated with vitamin supplementation aimed at lowering homocysteine levels (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Secondary prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with venous thrombosis NOT be treated with vitamin supplementation aimed at lowering homocysteine levels (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Venous thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the negative results in secondary prevention, we suggest NOT administering vitamin supplementation for the purpose of lowering homocysteine levels for primary prevention (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Supplementation in the general population'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/1\">",
"      Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/2\">",
"      McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/3\">",
"      Kang SS. Critical points for determining moderate hyperhomocyst(e)inaemia. Eur J Clin Invest 1995; 25:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/4\">",
"      Andersson A, Brattstr&ouml;m L, Israelsson B, et al. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992; 22:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/5\">",
"      Gaustadnes M, R&uuml;diger N, Rasmussen K, Ingerslev J. Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost 2000; 83:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/6\">",
"      D'Angelo A, Coppola A, Madonna P, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events. Thromb Haemost 2000; 83:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/7\">",
"      Mezzano D, Mu&ntilde;oz X, Mart&iacute;nez C, et al. Vegetarians and cardiovascular risk factors: hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost 1999; 81:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/8\">",
"      Refsum H, Ueland PM, Kvinnsland S. Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986; 46:5385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/9\">",
"      Smulders YM, de Man AM, Stehouwer CD, Slaats EH. Trimethoprim and fasting plasma homocysteine. Lancet 1998; 352:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/10\">",
"      Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs 2002; 62:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/11\">",
"      Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003; 171:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/12\">",
"      Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004; 3:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/13\">",
"      Bazzano LA, He J, Muntner P, et al. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/14\">",
"      Kang SS, Wong PW, Susmano A, et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/15\">",
"      Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/16\">",
"      Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/17\">",
"      Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (&gt; or = 40 micromol/liter). The Hordaland Homocysteine Study. J Clin Invest 1996; 98:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/18\">",
"      Harmon DL, Woodside JV, Yarnell JW, et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM 1996; 89:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/19\">",
"      Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/20\">",
"      Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998; 97:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/21\">",
"      Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/22\">",
"      Voutilainen S, Rissanen TH, Virtanen J, et al. Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study. Circulation 2001; 103:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/23\">",
"      Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000; 355:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/24\">",
"      Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/25\">",
"      Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/26\">",
"      Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/27\">",
"      McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/28\">",
"      Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/29\">",
"      Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974; 291:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/30\">",
"      Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995; 91:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/31\">",
"      Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994; 91:6369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/32\">",
"      Poddar R, Sivasubramanian N, DiBello PM, et al. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001; 103:2717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/33\">",
"      Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/34\">",
"      Al-Obaidi MK, Philippou H, Stubbs PJ, et al. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation 2000; 101:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/35\">",
"      Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/36\">",
"      Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/37\">",
"      Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/38\">",
"      Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/39\">",
"      Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/40\">",
"      Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79:2930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/41\">",
"      Mansoor MA, Bergmark C, Svardal AM, et al. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol 1995; 15:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/42\">",
"      Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/43\">",
"      Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/44\">",
"      McCully KS, Carvalho AC. Homocysteine thiolactone, N-homocysteine thiolactonyl retinamide, and platelet aggregation. Res Commun Chem Pathol Pharmacol 1987; 56:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/45\">",
"      St&uuml;hlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/46\">",
"      Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/47\">",
"      Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/48\">",
"      Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/49\">",
"      Title LM, Cummings PM, Giddens K, et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000; 36:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/50\">",
"      Willems FF, Aengevaeren WR, Boers GH, et al. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002; 40:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/51\">",
"      Thambyrajah J, Landray MJ, Jones HJ, et al. A randomized double-blind placebo-controlled trial of the effect of homocysteine-lowering therapy with folic acid on endothelial function in patients with coronary artery disease. J Am Coll Cardiol 2001; 37:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/52\">",
"      van Guldener C, Stehouwer CD. Hyperhomocysteinaemia and vascular disease--a role for DNA hypomethylation? Lancet 2003; 361:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/53\">",
"      Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003; 361:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/54\">",
"      Kang SS, Wong PW. Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis 1996; 119:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/55\">",
"      Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/56\">",
"      Dudman NP, Wilcken DE, Wang J, et al. Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb 1993; 13:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/57\">",
"      Al-Obaidi MK, Stubbs PJ, Amersey R, Noble MI. Acute and convalescent changes in plasma homocysteine concentrations in acute coronary syndromes. Heart 2001; 85:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/58\">",
"      Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med 2000; 160:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/59\">",
"      Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/60\">",
"      Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/61\">",
"      Cleophas TJ, Hornstra N, van Hoogstraten B, van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol 2000; 86:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/62\">",
"      Fallon UB, Ben-Shlomo Y, Elwood P, et al. Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up. Heart 2001; 85:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/63\">",
"      Knekt P, Reunanen A, Alfthan G, et al. Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med 2001; 161:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/64\">",
"      Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/65\">",
"      Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C--&gt;T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002; 288:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/66\">",
"      Kohara K, Fujisawa M, Ando F, et al. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA Study. Stroke 2003; 34:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/67\">",
"      Humphrey LL, Fu R, Rogers K, et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/68\">",
"      Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/69\">",
"      Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/70\">",
"      Giles WH, Croft JB, Greenlund KJ, et al. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey. Am Heart J 2000; 139:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/71\">",
"      Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/72\">",
"      Al-Obaidi MK, Stubbs PJ, Collinson P, et al. Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes. J Am Coll Cardiol 2000; 36:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/73\">",
"      Matetzky S, Freimark D, Ben-Ami S, et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med 2003; 163:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/74\">",
"      Soinio M, Marniemi J, Laakso M, et al. Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus. Ann Intern Med 2004; 140:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/75\">",
"      Genest JJ Jr, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb 1991; 11:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/76\">",
"      Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/77\">",
"      Nyg&aring;rd O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/78\">",
"      Anderson JL, Muhlestein JB, Horne BD, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation 2000; 102:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/79\">",
"      Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation 2000; 101:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/80\">",
"      Schnyder G, Flammer Y, Roffi M, et al. Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol 2002; 40:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/81\">",
"      Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/82\">",
"      Malinow MR, Nieto FJ, Szklo M, et al. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993; 87:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/83\">",
"      McQuillan BM, Beilby JP, Nidorf M, et al. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation 1999; 99:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/84\">",
"      Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C--&gt;T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002; 59:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/85\">",
"      McIlroy SP, Dynan KB, Lawson JT, et al. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. Stroke 2002; 33:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/86\">",
"      Tanne D, Haim M, Goldbourt U, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003; 34:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/87\">",
"      Li Z, Sun L, Zhang H, et al. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. Stroke 2003; 34:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/88\">",
"      Iso H, Moriyama Y, Sato S, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004; 109:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/89\">",
"      Boysen G, Brander T, Christensen H, et al. Homocysteine and risk of recurrent stroke. Stroke 2003; 34:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/90\">",
"      Kim NK, Choi BO, Jung WS, et al. Hyperhomocysteinemia as an independent risk factor for silent brain infarction. Neurology 2003; 61:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/91\">",
"      Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003; 289:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/92\">",
"      Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/93\">",
"      Casas JP, Bautista LE, Smeeth L, et al. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005; 365:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/94\">",
"      Hankey GJ, Eikelboom JW. Homocysteine and stroke. Lancet 2005; 365:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/95\">",
"      Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C-&gt;T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ 2005; 331:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/96\">",
"      He K, Merchant A, Rimm EB, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 2004; 35:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/97\">",
"      McNulty H, Dowey le RC, Strain JJ, et al. Riboflavin lowers homocysteine in individuals homozygous for the MTHFR 677C-&gt;T polymorphism. Circulation 2006; 113:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/98\">",
"      Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/99\">",
"      Bostom AG, Jacques PF, Nadeau MR, et al. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995; 116:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/100\">",
"      Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. Am J Clin Nutr 1994; 59:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/101\">",
"      Hung J, Beilby JP, Knuiman MW, Divitini M. Folate and vitamin B-12 and risk of fatal cardiovascular disease: cohort study from Busselton, Western Australia. BMJ 2003; 326:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/102\">",
"      den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/103\">",
"      Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/104\">",
"      den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/105\">",
"      Eichinger S, St&uuml;mpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/106\">",
"      Margaglione M, D'Andrea G, d'Addedda M, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998; 79:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/107\">",
"      Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/108\">",
"      De Stefano V, Casorelli I, Rossi E, et al. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost 2000; 26:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/109\">",
"      Tsai AW, Cushman M, Tsai MY, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 2003; 72:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/110\">",
"      Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C-&gt;T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med 2007; 167:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/111\">",
"      Naess IA, Christiansen SC, Romundstad PR, et al. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population--results from the HUNT 2 study. Br J Haematol 2008; 141:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/112\">",
"      Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/113\">",
"      Kirke PN, Mills JL, Molloy AM, et al. Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. BMJ 2004; 328:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/114\">",
"      van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/115\">",
"      McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/116\">",
"      Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, et al. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005; 20:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/117\">",
"      Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005; 118:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/118\">",
"      Gerdhem P, Ivaska KK, Isaksson A, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 2007; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/119\">",
"      Sato Y, Honda Y, Iwamoto J, et al. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 2005; 293:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/120\">",
"      Smith SC Jr, Milani RV, Arnett DK, et al. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 2004; 109:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/121\">",
"      Wilson PW. Homocysteine and coronary heart disease: how great is the hazard? JAMA 2002; 288:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/122\">",
"      Stampfer MJ, Malinow MR. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/123\">",
"      Rosenson RS, Tangney CC. Preanalytical sources of measurement error: the conundrum of the homocysteine hypothesis. Atherosclerosis 2007; 194:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/124\">",
"      Kang SS. Treatment of hyperhomocyst(e)inemia: physiological basis. J Nutr 1996; 126:1273S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/125\">",
"      Appel LJ, Miller ER 3rd, Jee SH, et al. Effect of dietary patterns on serum homocysteine: results of a randomized, controlled feeding study. Circulation 2000; 102:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/126\">",
"      Brattstr&ouml;m L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/127\">",
"      Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998; 338:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/128\">",
"      Neal B, MacMahon S, Ohkubo T, et al. Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease. Eur Heart J 2002; 23:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/129\">",
"      Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006; 296:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/130\">",
"      Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007; 369:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/131\">",
"      Mart&iacute;-Carvajal AJ, Sol&agrave; I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009; :CD006612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/132\">",
"      Miller ER 3rd, Juraschek S, Pastor-Barriuso R, et al. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol 2010; 106:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/133\">",
"      Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis. Stroke 2010; 41:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/134\">",
"      Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/135\">",
"      Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011; 378:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/136\">",
"      Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002; 288:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/137\">",
"      Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004; 350:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/138\">",
"      Herrmann HC. Prevention of cardiovascular events after percutaneous coronary intervention. N Engl J Med 2004; 350:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/139\">",
"      den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007; 109:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/140\">",
"      Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med 2007; 146:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/141\">",
"      Eikelboom JW, Lonn E, Genest J Jr, et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/142\">",
"      Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ 1998; 316:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/37/19034/abstract/143\">",
"      Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001; 161:695.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6837 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19034=[""].join("\n");
var outline_f18_37_19034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY OF HYPERHOMOCYSTEINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Thermolabile variant of MTHFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vitamin deficiencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ATHEROTHROMBOTIC PROPERTIES OF HOMOCYSTEINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ROLE IN VASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hyperhomocysteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vitamin status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ROLE IN VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Obstetric complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ROLE IN OTHER CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Birth defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SCREENING FOR HYPERHOMOCYSTEINEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lowering homocysteine levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - After PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUPPLEMENTATION IN THE GENERAL POPULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6837\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6837|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/40/7814\" title=\"figure 1\">",
"      Homocysteine metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/48/22285\" title=\"figure 2\">",
"      Homocysteine carotid stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/7/5247\" title=\"figure 3\">",
"      Folate and alcohol intake and CHD risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6837|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/55/22395\" title=\"table 1\">",
"      Methionine challenge",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10073?source=related_link\">",
"      The child with tall stature or abnormally rapid growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_37_19035="Efficiency Down syndrome screen";
var content_f18_37_19035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficiency of Down syndrome screening tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test*",
"       </td>",
"       <td class=\"subtitle1\">",
"        FPR percent for 85 percent DR",
"       </td>",
"       <td class=\"subtitle1\">",
"        DR for 5 percent FPR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Integrated test with nuchal translucency (1, 2)",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum integrated test (1,2)",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combined test (1)",
"       </td>",
"       <td>",
"        4.3",
"       </td>",
"       <td>",
"        86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quadruple test (2)",
"       </td>",
"       <td>",
"        6.2",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triple test (2)",
"       </td>",
"       <td>",
"        9.3",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FPR: false positive rate; DR: detection rate; ( ): numbers in parentheses refer to trimester that test is obtained.",
"     <br>",
"      * All consider maternal age.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wald NJ, Rodeck C, Hackshaw AK, et al. SURUSS in perspective. BJOG 2004; 111:521.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19035=[""].join("\n");
var outline_f18_37_19035=null;
var title_f18_37_19036="Treatment of neuronopathic GD";
var content_f18_37_19036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of European consensus guidelines for treatment of neuronopathic Gaucher disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Enzyme replacement therapy (ERT) with imiglucerase is the treatment of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Indications:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patients with",
"        <strong>",
"         chronic",
"        </strong>",
"        neuronopathic Gaucher disease*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Siblings of patients with neuronopathic Gaucher disease who are proven to have Gaucher disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patients with the following high-risk genotypes:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - L444P/L444P (c.1448T&gt;C homozygote)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - D409H/D409H (c.1342G&gt;C homozygote)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        - L444P/D409H (c.1448T&gt;C/c.1342G&gt;C heterozygote)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Onset of severe systemic Gaucher disease at &le;2 years of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Dose:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        60 units/kg every two weeks&bull;, initiated as soon as possible after diagnosis or identification.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Duration:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Treatment with 60 units/kg every two weeks should be continued until the patient attains adulthood and clearly has mild Gaucher disease and stable neurologic involvement. At this point a dosage reduction (to as low as 30 units/kg every two weeks) may be considered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Splenectomy:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Total splenectomy should be avoided if at all possible. Partial, rather than total, splenectomy should be considered if splenectomy is required in an emergency situation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * ERT is",
"     <strong>",
"      not",
"     </strong>",
"     recommended for patients with acute disease.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Higher doses may be necessary to control visceral disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Vellodi A, Bembi B, de Villemeur TB, et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 2001; 24:319 and Vellodi A, Tylki-Szymanska A, Davies EH, et al. Management of neuronopathic Gaucher disease: Revised recommendations. J Inherit Metab Dis 2009; 32:660.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19036=[""].join("\n");
var outline_f18_37_19036=null;
var title_f18_37_19037="Comorbidity anorexia nervosa with other DSM-IV Axis I disorders";
var content_f18_37_19037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F57877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F57877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lifetime comorbidity of anorexia nervosa with other DSM-IV Axis I disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Axis I disorder",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Percent of anorexia nervosa patients with a comorbid disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Epidemiologic survey",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clinical settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Anxiety disorder",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        48",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Specific phobias",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Social phobia",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Posttraumatic stress disorder",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Generalized anxiety disorder",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Agoraphobia",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Panic disorder",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obsessive-compulsive disorder",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Mood disorder",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        42",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unipolar major depression",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dysthymic disorder",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bipolar I or II disorder",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Impulse control disorder",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        31",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Attention-deficit/hyperactivity disorder",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oppositional-defiant disorder",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conduct disorder",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intermittent explosive disorder",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\">",
"        Substance use disorder",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        27",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol abuse or dependence",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Illicit drug abuse or dependence",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Bulik CM, Klump KL, Thornton L, et al. Alcohol use disorder comorbidity in eating disorders: a multicenter study. J Clin Psychiatry 2004; 65:1000.",
"       </li>",
"       <li>",
"        Fern&aacute;ndez-Aranda F, Pinheiro AP, Thornton LM, et al. Impulse control disorders in women with eating disorders. Psychiatry Res 2008; 157:147.",
"       </li>",
"       <li>",
"        Fern&aacute;ndez-Aranda F, Pinheiro AP, Tozzi F, et al. Symptom profile of major depressive disorder in women with eating disorders. Aust N Z J Psychiatry 2007; 41:24.",
"       </li>",
"       <li>",
"        Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61:348.",
"       </li>",
"       <li>",
"        Kaye WH, Bulik CM, Thornton L, et al. Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry 2004; 161:2215.",
"       </li>",
"       <li>",
"        Root TL, Pinheiro AP, Thornton L, et al. Substance use disorders in women with anorexia nervosa. Int J Eat Disord 2010; 43:14.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19037=[""].join("\n");
var outline_f18_37_19037=null;
var title_f18_37_19038="Classification jaundice II";
var content_f18_37_19038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classification of jaundice due to both conjugated and unconjugated hyperbilirubinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19038=[""].join("\n");
var outline_f18_37_19038=null;
var title_f18_37_19039="Gram stain CSF 6C with answer";
var content_f18_37_19039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcus neoformans on Sabouraud's agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Culture of Cryptococcus neoformans on Sabouraud's agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_37_19039=[""].join("\n");
var outline_f18_37_19039=null;
